

CITATION REPORT

List of articles citing

PD-1 and its ligands in tolerance and immunity

DOI: 10.1146/annurev.immunol.26.021607.090331
Annual Review of Immunology, 2008, 26, 677-704.

Source: <https://exaly.com/paper-pdf/43569830/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2282	Plasma fibrinogen levels and the clinical course of acute myocardial infarction. 1983 , 34, 693-8		20
2281	Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation. 2017 , 6, 148-158		26
2280	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. 2017 , 6, 220-229		9
2279	Islet glia, neurons, and beta cells. 2008 , 1150, 32-42		22
2278	Tumor dormancy and immunoescape. 2008 , 116, 685-94		75
2277	Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. 2008 , 223, 317-33		75
2276	Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. 2008 , 224, 141-65		182
2275	Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. 2008 , 224, 166-82		650
2274	PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. 2008 , 21, 1015-28		37
2273	Local and systemic gene expression responses of Atlantic salmon (<i>Salmo salar</i> L.) to infection with the salmon louse (<i>Lepeophtheirus salmonis</i>). 2008 , 9, 498		120
2272	Ethylenecarbodiimide-coupled allogeneic antigen presenting cells induce human CD4+ regulatory T cells. 2008 , 129, 381-93		2
2271	CD8+ T cells in type 1 diabetes. 2008 , 100, 79-124		85
2270	Therapeutic vaccination for hepatitis C: can protective T-cell responses be restored after prolonged antigen exposure?. 2008 , 134, 1601-4		5
2269	Strategies to cure experimental autoimmune colitis using antigen-specific Foxp3+ regulatory T cells. 2008 , 134, 2171-4		1
2268	Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. 2008 , 105, 10275-6		45
2267	Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice. 2008 , 69, 790-6		22
2266	Interaction of human PD-L1 and B7-1. 2008 , 45, 3567-72		184

2265	The complex role of B7 molecules in tumor immunology. 2008 , 14, 550-9	71
2264	Cancer immunotherapy by dendritic cells. 2008 , 29, 372-83	407
2263	Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. 2008 , 82, 11536-44	61
2262	Tuberculosis in Africa: learning from pathogenesis for biomarker identification. 2008 , 4, 219-28	73
2261	Unraveling the role of PD-1/PD-L interactions in persistent hepatotropic infections: potential for therapeutic application?. 2008 , 134, 2168-71	20
2260	A monoclonal antibody to <i>Histoplasma capsulatum</i> alters the intracellular fate of the fungus in murine macrophages. 2008 , 7, 1109-17	33
2259	Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. 2008 , 181, 2513-21	124
2258	Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. 2008 , 82, 9808-22	79
2257	IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. 2008 , 105, 20428-33	154
2256	Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). 2008 , 105, 20852-7	514
2255	Cutting edge: Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. 2008 , 181, 6707-10	112
2254	The use of the inhibitory receptors for modulating the immune responses. 2008 , 14, 2643-50	17
2253	Function is the key: impact of interferon on HCV-specific CD8+T cells during acute HCV infection. 2008 , 3, 537-542	
2252	PD-1 tempers Tregs in chronic HCV infection. 2009 , 119, 450-3	30
2251	Soluble PD-1 is associated with aberrant regulation of T cells activation in aplastic anemia. 2009 , 38, 408-21	28
2250	A protective role for C5a in the development of allergic asthma associated with altered levels of B7-H1 and B7-DC on plasmacytoid dendritic cells. 2009 , 182, 5123-30	59
2249	Epithelium, inflammation, and immunity in the upper airways of humans: studies in chronic rhinosinusitis. 2009 , 6, 288-94	79
2248	Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. 2009 , 183, 4984-93	66

2247	Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. 2009 , 15, 971-9	599
2246	Culling of activated CD4 T cells during typhoid is driven by Salmonella virulence genes. 2009 , 182, 7838-45	37
2245	PD-1/PD-L blockade prevents energy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. 2009 , 182, 2816-26	148
2244	Bim-mediated apoptosis is not necessary for thymic negative selection to ubiquitous self-antigens. 2009 , 183, 7761-7	27
2243	Cutting edge: CD28 engagement releases antigen-activated invariant NKT cells from the inhibitory effects of PD-1. 2009 , 182, 6644-7	29
2242	Differential association of programmed death-1 and CD57 with ex vivo survival of CD8+ T cells in HIV infection. 2009 , 183, 1120-32	88
2241	Identification of QTLs that modify peripheral neuropathy in NOD.H2b-Pdcd1 ^{-/-} mice. 2009 , 21, 499-509	8
2240	Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. 2009 , 182, 2102-12	93
2239	The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. 2009 , 83, 9652-62	234
2238	PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. 2009 , 106, 6303-8	335
2237	Unconventional antigen-presenting cells in the induction of peripheral CD8(+) T cell tolerance. 2009 , 86, 795-801	11
2236	Palettes of vaccines and immunostimulatory monoclonal antibodies for combination. 2009 , 15, 1507-9	22
2235	Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases. 2009 , 1, 385-401	7
2234	Inhibitors of B7-CD28 costimulation in urologic malignancies. 2009 , 1, 129-39	9
2233	Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. 2009 , 183, 7898-908	55
2232	Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. 2009 , 69, 8067-75	258
2231	The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. 2009 , 69, 5514-21	149
2230	Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus. 2009 , 18, 501-7	31

2229	Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. 2009 , 206, 1327-37	615
2228	Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. 2009 , 15, 1623-34	155
2227	Cutting edge: B and T lymphocyte attenuator signaling on NKT cells inhibits cytokine release and tissue injury in early immune responses. 2009 , 183, 32-6	41
2226	Target-dependent B7-H1 regulation contributes to clearance of central nervous system infection and dampens morbidity. 2009 , 182, 5430-8	57
2225	Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. 2009 , 15, 6341-7	201
2224	Intracerebral Mycobacterium bovis bacilli Calmette-Guerin infection-induced immune responses in the CNS. 2009 , 213, 112-22	11
2223	Depletion of the programmed death-1 receptor completely reverses established clonal anergy in CD4(+) T lymphocytes via an interleukin-2-dependent mechanism. 2009 , 256, 86-91	17
2222	Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. 2009 , 36, S27-35	34
2221	Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. 2009 , 39, 902-11	79
2220	B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function. 2009 , 39, 3084-90	46
2219	IL-33 promotes DC development in BM culture by triggering GM-CSF production. 2009 , 39, 3331-42	52
2218	A novel subpopulation of B-1 cells is enriched with autoreactivity in normal and lupus-prone mice. 2009 , 60, 3734-43	48
2217	siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8(+) T cells from HIV-1-infected individuals. 2009 , 29, 637-45	20
2216	Mast cells as regulators of adaptive immunity to tumours. 2009 , 155, 140-6	66
2215	Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. 2009 , 157, 9-19	111
2214	Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals. 2009 , 157, 90-7	37
2213	Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host. 2009 , 6, 3-13	67
2212	Sepsis induces extensive autophagic vacuolization in hepatocytes: a clinical and laboratory-based study. 2009 , 89, 549-61	116

2211	Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. 2009 , 10, 1185-92	530
2210	PD-1 signaling in primary T cells. 2009 , 229, 114-25	504
2209	Mechanisms of costimulation. 2009 , 229, 5-11	235
2208	Effector and regulatory mechanisms in allergic contact dermatitis. 2009 , 64, 1699-714	229
2207	PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. 2009 , 206, 3015-29	1384
2206	Interactions between programmed death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene polymorphisms in type 1 diabetes. 2009 , 83, 289-94	26
2205	SnapShot: B7/CD28 costimulation. 2009 , 137, 974-4.e1	31
2204	The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. 2009 , 46, 457-72	81
2203	Immune therapy for cancer. <i>Annual Review of Immunology</i> , 2009 , 27, 83-117	34-7 476
2202	Biomarkers of latent TB infection. 2009 , 3, 387-401	20
2201	High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. 2009 , 27, 1470-6	245
2200	Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. 2009 , 174, 2290-9	30
2199	Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. 2009 , 57, 409-23	13
2198	Suppression of human T-cell activation and expansion of regulatory T cells by pig cells overexpressing PD-ligands. 2009 , 87, 975-82	34
2197	Targeted delivery of siRNA to cell death proteins in sepsis. 2009 , 32, 131-9	34
2196	NKp80 defines and stimulates a reactive subset of CD8 T cells. 2009 , 113, 358-69	40
2195	Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. 2009 , 114, 1537-44	1123
2194	Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity. 2009 , 113, 6351-60	172

2193	B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. 2009 , 114, 2149-58	162
2192	Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. 2009 , 114, 3101-12	233
2191	Blocking PD-1 in cancer immunotherapy. 2009 , 114, 1457-8	23
2190	Taking aim at protein translation in AML. 2009 , 114, 1458-9	7
2189	Beyond IL-17: new cytokines in the pathogenesis of HIV infection. 2010 , 5, 184-8	9
2188	B7-H1 expression in vestibular schwannomas. 2010 , 31, 991-7	24
2187	Stimulatory and inhibitory receptor interactions in xenotransplantation. 2010 , 15, 219-23	5
2186	HIV-associated chronic immune activation: current understandings and therapeutic intervention. 2010 , 4, 161-177	1
2185	Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance. 2010 , 116, 2266-76	61
2184	Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. 2010 , 115, 2397-406	57
2183	Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. 2010 , 116, 3311-20	138
2182	Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. 2010 , 116, 3268-77	903
2181	Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. 2010 , 116, 2484-93	211
2180	Immunology of beta-cell destruction. 2010 , 654, 537-83	21
2179	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. 2010 , 59, 1173-83	44
2178	In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. 2010 , 59, 1839-49	121
2177	Costimulation of Th17 cells: Adding fuel or putting out the fire in the inflamed gut?. 2010 , 32, 55-70	4
2176	Gatekeepers of intestinal inflammation. 2010 , 59, 1-14	13

2175	Future vaccination strategies against tuberculosis: thinking outside the box. 2010 , 33, 567-77	134
2174	A dimeric structure of PD-L1: functional units or evolutionary relics?. 2010 , 1, 153-60	50
2173	Structural immunology of costimulatory and coinhibitory molecules. 2010 , 53, 183-9	5
2172	Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful?. 2010 , 92, 246-54	29
2171	Association between hepatitis B viral burden in chronic infection and a functional single nucleotide polymorphism of the PDCD1 gene. 2010 , 30, 855-60	21
2170	Biology and clinical applications of CD40 in cancer treatment. 2010 , 37, 517-23	37
2169	Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. 2010 , 37, 430-9	230
2168	T cell stimulator cells, an efficient and versatile cellular system to assess the role of costimulatory ligands in the activation of human T cells. 2010 , 362, 131-41	47
2167	PD-1, gender, and autoimmunity. 2010 , 9, 583-7	64
2166	A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients. 2010 , 38, 124-31	29
2165	Programmed death-1/B7-H1 negative costimulation protects mouse liver against ischemia and reperfusion injury. 2010 , 52, 1380-9	53
2164	Chitin induces upregulation of B7-H1 on macrophages and inhibits T-cell proliferation. 2010 , 40, 2882-90	18
2163	Robust genital gag-specific CD8+ T-cell responses in mice upon intramuscular immunization with simian adenoviral vectors expressing HIV-1-gag. 2010 , 40, 3426-38	11
2162	B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis. 2010 , 40, 3117-27	54
2161	Lower expression levels of the programmed death 1 receptor on CD4+CD25+ T cells and correlation with the PD-1.3A genotype in patients with systemic lupus erythematosus. 2010 , 62, 1702-11	49
2160	The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. 2010 , 62, 1870-80	85
2159	Interferon- β -dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 2010 , 62, 2776-86	136
2158	Role of PD-1 in regulating acute infections. 2010 , 22, 397-401	104

2157	Cytokine induced expression of programmed death ligands in human neutrophils. 2010 , 129, 100-7	26
2156	The PD-1 pathway in tolerance and autoimmunity. 2010 , 236, 219-42	1437
2155	PD-1 signalling in CD4(+) T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. 2010 , 130, 92-102	20
2154	Novel tuberculosis vaccination strategies based on understanding the immune response. 2010 , 267, 337-53	34
2153	Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy?. 2010 , 161, 118-26	10
2152	Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection. 2010 , 161, 315-23	12
2151	Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer. 2010 , 7, 389-95	193
2150	Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. 2010 , 11, 55-66	15
2149	TNFR1 is a positive T-cell costimulatory molecule important for the timing of cytokine responses. 2010 , 88, 586-95	11
2148	Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. 2010 , 24, 1160-70	378
2147	Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. 2010 , 16, 452-9	328
2146	Prostate cancer as a model for tumour immunotherapy. 2010 , 10, 580-93	272
2145	Langerin-expressing dendritic cells in gut-associated lymphoid tissues. 2010 , 234, 233-46	27
2144	The immunology of corneal xenotransplantation: a review of the literature. 2010 , 17, 338-49	49
2143	Regulation of T-cell chemotaxis by programmed death-ligand 1 (PD-L1) in dry eye-associated corneal inflammation. 2010 , 51, 3418-23	50
2142	Unexpected acceleration of type 1 diabetes by transgenic expression of B7-H1 in NOD mouse peri-islet glia. 2010 , 59, 2588-96	15
2141	Enhanced PD-1 expression by T cells in cerebrospinal fluid does not reflect functional exhaustion during chronic human immunodeficiency virus type 1 infection. 2010 , 84, 131-40	11
2140	Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation. 2010 , 22, 905-13	34

2139	PD-1-PD-L1 pathway impairs T(h)1 immune response in the late stage of infection with <i>Mycobacterium bovis</i> bacillus Calmette-Guérin. 2010 , 22, 915-25	35
2138	Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. 2010 , 184, 2410-22	14
2137	Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion. 2010 , 84, 2078-89	92
2136	Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells. 2010 , 59, 1966-73	32
2135	Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in herpes simplex virus type 1-infected mice. 2010 , 84, 12315-24	18
2134	Activation-induced accumulation of B and T lymphocyte attenuator at the immunological synapse in CD4+ T cells. 2010 , 87, 425-32	13
2133	Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors. 2010 , 184, 4696-707	80
2132	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. 2010 , 116, 2286-94	595
2131	PD-L1(hi) retinal pigment epithelium (RPE) cells elicited by inflammatory cytokines induce regulatory activity in uveitogenic T cells. 2010 , 88, 1241-9	23
2130	Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. 2010 , 107, 14733-8	555
2129	Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. 2010 , 28, 3167-75	2163
2128	Memory T Cells. 2010 ,	1
2127	Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. 2010 , 185, 5082-92	57
2126	Keratinocyte-associated B7-H1 directly regulates cutaneous effector CD8+ T cell responses. 2010 , 184, 4918-25	30
2125	Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. 2010 , 16, 6019-28	144
2124	Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. 2010 , 185, 7340-8	39
2123	Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways. 2011 , 344, 245-67	36
2122	PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. 2010 , 22, 651-60	158

2121	Early signals during CD8 T cell priming regulate the generation of central memory cells. 2010 , 185, 263-72	88
2120	Costimulator B7-DC attenuates strong Th2 responses induced by <i>Nippostrongylus brasiliensis</i> . 2010 , 184, 2086-94	35
2119	Endothelial cells augment the suppressive function of CD4+ CD25+ Foxp3+ regulatory T cells: involvement of programmed death-1 and IL-10. 2010 , 184, 5562-70	39
2118	B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. 2010 , 185, 2747-53	99
2117	Short-term administrations of a combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induce tolerance to neonatal porcine islet xenografts in mice. 2010 , 59, 958-66	34
2116	B7-H1 (programmed cell death ligand 1) is required for the development of multifunctional Th1 cells and immunity to primary, but not secondary, <i>Salmonella</i> infection. 2010 , 185, 2442-9	16
2115	Stimulation of B7-H1 in hepatocarcinoma cells by hepatitis B virus X antigen. 2010 , 39, 754-69	4
2114	Expression profiling of genes associated with regulatory functions of T-cell subsets in Marek's disease virus-infected chickens. 2010 , 39, 367-73	12
2113	Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. 2010 , 185, 3768-76	43
2112	Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. 2010 , 8, e1000302	70
2111	Enhanced antiviral T cell function in the absence of B7-H1 is insufficient to prevent persistence but exacerbates axonal bystander damage during viral encephalomyelitis. 2010 , 185, 5607-18	34
2110	Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. 2010 , 23, 1393-403	122
2109	Immunotherapy to overcome lung tumor cell-induced escape from immunosurveillance. 2010 , 2, 757-60	2
2108	Adaptive immunity to the hepatitis C virus. 2010 , 78, 43-86	53
2107	Co-inhibitory molecules: Controlling the effectors or controlling the controllers?. 2010 , 1, 77-88	15
2106	Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. 2010 , 2, 561-74	17
2105	A complex role for complement in allergic asthma. 2010 , 6, 269-77	62
2104	Immunotherapy for prostate cancer: an emerging treatment modality. 2010 , 37, 121-9, Table of Contents	9

2103	Signaling amplification at the immunological synapse. 2010 , 340, 109-22	14
2102	New perspectives on immunomodulatory therapy for bacteraemia and sepsis. 2010 , 36 Suppl 2, S70-3	27
2101	BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. 2010 , 105, 193-210	205
2100	Lack of retinoic acid leads to increased langerin-expressing dendritic cells in gut-associated lymphoid tissues. 2010 , 138, 1468-78, 1478.e1-6	38
2099	Role of PD-1 in regulating T-cell immunity. 2011 , 350, 17-37	198
2098	Dominant processes during human dendritic cell maturation revealed by integration of proteome and transcriptome at the pathway level. 2010 , 9, 1727-37	22
2097	PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. 2010 , 14, R220	196
2096	New vaccines for tuberculosis. 2010 , 375, 2110-9	226
2095	CD4 T cells in hepatic immune tolerance. 2010 , 34, 23-8	47
2094	Pre-existing autoimmunity determines type 1 diabetes outcome after Flt3-ligand treatment. 2010 , 34, 445-52	17
2093	Identification of PDL-1 as a novel biomarker of sensitizer exposure in dendritic-like cells. 2010 , 24, 1727-35	11
2092	Structure and function of programmed death (PD) molecules. 2010 , 134, 33-8	19
2091	Feline programmed death and its ligand: characterization and changes with feline immunodeficiency virus infection. 2010 , 134, 107-14	17
2090	Chemically Induced Allergy and Autoimmunity. 2010 , 361-374	
2089	Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis. 2010 , 88, 233-40	203
2088	Mechanisms of self-inactivation in anergic T cells. 2010 , 29, 20-33	0
2087	Tolerance: an overview and perspectives. 2010 , 6, 569-76	35
2086	Functional anatomy of T cell activation and synapse formation. <i>Annual Review of Immunology</i> , 2010 , 28, 79-105	34.7 338

2085	Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM. <i>Annual Review of Immunology</i> , 2010 , 28, 389-411	34.7	162
2084	The Immune Response to Infectious Agents. 2010 , 37, 1-20		0
2083	The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. 2011 , 187, 4530-41		125
2082	Immunotherapy with tolerogenic apolipoprotein B-100-loaded dendritic cells attenuates atherosclerosis in hypercholesterolemic mice. 2011 , 123, 1083-91		143
2081	Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. 2011 , 29, 1812-26		283
2080	The dermis as a portal for dendritic cell-targeted immunotherapy of cutaneous melanoma. 2012 , 351, 181-220		12
2079	The pathogenesis of sepsis. 2011 , 6, 19-48		381
2078	Immunomodulatory therapy for sepsis: an update. 2011 , 9, 1013-33		39
2077	Success and failure of virus-specific T cell responses in hepatitis C virus infection. 2011 , 29, 416-22		23
2076	Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade. 2011 , 42, 103		55
2075	Cancer Immunology and Immunotherapy. 2011 ,		1
2074	Immunotherapy for renal cell carcinoma. 2011 , 25, 793-812		22
2073	Cancer immunotherapy comes of age. 2011 , 480, 480-9		2374
2072	A novel function for programmed death ligand-1 regulation of angiogenesis. 2011 , 178, 1922-9		44
2071	A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. 2011 , 145, 268-83		106
2070	Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. 2011 , 56, 231-8		155
2069	Targeted immunotherapy for acute myeloid leukemia. 2011 , 24, 533-40		6
2068	Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. 2011 , 17, 1133-45		126

2067	Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasis. 2011 , 36, 301-12	42
2066	The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants. 2011 , 216, 918-24	13
2065	PPAR- β signaling and IL-5 inhibition together prevent chronic rejection of MHC Class II-mismatched cardiac grafts. 2011 , 30, 698-706	10
2064	Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. 2011 , 42, 552-7	85
2063	Fact and fiction in tuberculosis vaccine research: 10 years later. 2011 , 11, 633-40	83
2062	Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. 2011 , 15, R70	158
2061	Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. 2011 , 15, R99	191
2060	Follicular helper CD4 T cells (TFH). <i>Annual Review of Immunology</i> , 2011 , 29, 621-63	34.7 1928
2059	Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens. 2011 , 187, 5183-95	45
2058	Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection. 2011 , 80-191	10
2057	Immunogenicity and Immune-Modulating Properties of Human Stem Cells. 2011 ,	2
2056	Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. 2011 , 17, 3322-9	104
2055	Mouse conjunctival forniceal gene expression during postnatal development and its regulation by Kruppel-like factor 4. 2011 , 52, 4951-62	22
2054	Targeting co-stimulatory pathways in gene therapy. 2011 , 2, 202	2
2053	Lack of an association of PD-1 and its ligand genes with Behcet's disease in a Chinese Han population. 2011 , 6, e25345	12
2052	Role of immunotherapy for renal cell cancer in 2011. 2011 , 9, 1011-8	21
2051	Evaluation of current cancer immunotherapy: hemato-oncology. 2011 , 17, 309-24	14
2050	Xenotransplantation--the future of corneal transplantation?. 2011 , 30, 371-8	99

2049	PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. 2011 , 34, 409-18	232
2048	Enhancement of vaccine-induced primary and memory CD8(+) T-cell responses by soluble PD-1. 2011 , 34, 297-306	81
2047	A Current Understanding of Ocular Immune Privilege. 2011 , 7, 336-343	6
2046	Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. 2011 , 11, 734-51	81
2045	PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. 2011 , 117, 1030-41	66
2044	CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse. 2011 , 118, 4480-8	19
2043	The molecular pathogenesis of primary mediastinal large B-cell lymphoma. 2011 , 118, 2659-69	155
2042	Role of PD-L1 and PD-L2 in allergic diseases and asthma. 2011 , 66, 155-62	83
2041	Stimulation of a shorter duration in the state of anergy by an invariant natural killer T cell agonist enhances its efficiency of protection from type 1 diabetes. 2011 , 164, 26-41	10
2040	Structure-guided design of an invariant natural killer T cell agonist for optimum protection from type 1 diabetes in non-obese diabetic mice. 2011 , 166, 121-33	16
2039	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. 2011 , 241, 104-18	185
2038	Dendritic cell control of tolerogenic responses. 2011 , 241, 206-27	252
2037	The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells. 2011 , 40, 525-32	14
2036	The regulation of T-cell cytokine production by ICOS-B7H2 interactions at the human fetomaternal interface. 2011 , 89, 417-25	28
2035	Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination. 2011 , 18, 63-76	11
2034	The role of the PD-1 pathway in autoimmunity and peripheral tolerance. 2011 , 1217, 45-59	219
2033	Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts. 2011 , 11, 832-40	44
2032	Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. 2011 , 11, 2582-92	46

2031	TLR3 signaling is either protective or pathogenic for the development of Theiler's virus-induced demyelinating disease depending on the time of viral infection. 2011 , 8, 178	21
2030	Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I diabetes. 2011 , 11, 104-11	19
2029	The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. 2011 , 141, 338-47	55
2028	Cancer immunotherapy comes of age. 2011 , 29, 4828-36	336
2027	PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. 2011 , 129, 195-201	59
2026	Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis. 2011 , 30, 1181-7	16
2025	Programmed cell death 1 gene polymorphisms is associated with ankylosing spondylitis in Chinese Han population. 2011 , 31, 209-13	36
2024	Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma. 2011 , 60, 965-74	49
2023	Immunosuppressive tumor microenvironment in cervical cancer patients. 2011 , 4, 361-75	77
2022	On the Normativity of the Immune System. 2011 , 3, 29-39	2
2021	Relatively increased number of liver Foxp(3+) regulatory T cells against hepatic lesions in murine lupus. 2011 , 31, 476	3
2020	Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis. 2011 , 8, 155	40
2019	Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets. 2011 , 12, 53	37
2018	Conversion of intratumoral regulatory T cells by human gastric cancer cells is dependent on transforming growth factor- β . 2011 , 104, 571-7	23
2017	Systemic treatment of metastatic melanoma: new approaches. 2011 , 104, 425-9	10
2016	Severe mental retardation and recessive congenital methemoglobinemia in three Indian patients: compound heterozygous for NADH-cytochrome b5 reductase gene mutations. 2011 , 86, 327-9	15
2015	Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and Sjögren syndrome. 2011 , 86, 325-7	40
2014	The negative costimulatory molecule PD-1 modulates the balance between immunity and tolerance via miR-21. 2011 , 41, 1754-63	51

2013	Single-cell dynamics of mast cell-CD4+ CD25+ regulatory T cell interactions. 2011 , 41, 1872-82	27
2012	Intranasal but not intravenous delivery of the adjuvant β -galactosylceramide permits repeated stimulation of natural killer T cells in the lung. 2011 , 41, 3312-22	29
2011	Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. 2011 , 41, 1941-7	79
2010	The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells. 2011 , 59, 841-56	33
2009	Hepatic B7 homolog 1 expression is essential for controlling cold ischemia/reperfusion injury after mouse liver transplantation. 2011 , 54, 216-28	31
2008	Overall survival and PD-L1 expression in metastasized malignant melanoma. 2011 , 117, 2192-201	178
2007	PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. 2011 , 128, 887-96	299
2006	Cell surface signaling molecules in the control of immune responses: a tide model. 2011 , 34, 466-78	122
2005	T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF- β cytokine. 2011 , 35, 123-34	91
2004	Self-antigen presentation by dendritic cells and lymphoid stroma and its implications for autoimmunity. 2011 , 23, 138-45	22
2003	Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance. 2011 , 79, 112-26	45
2002	B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. 2011 , 71, 1235-43	74
2001	Immunity and immune suppression in human ovarian cancer. 2011 , 3, 539-56	83
2000	The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma. 2011 , 12, 1019-22	43
1999	Embryonic stem cell-derived hematopoietic stem cells: challenges in development, differentiation, and immunogenicity. 2011 , 11, 1621-37	10
1998	HIV-mediated phosphatidylinositol 3-kinase/serine-threonine kinase activation in APCs leads to programmed death-1 ligand upregulation and suppression of HIV-specific CD8 T cells. 2011 , 187, 2932-43	23
1997	Using monoclonal antibodies to stimulate antitumor cellular immunity. 2011 , 10, 1093-106	12
1996	Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. 2011 , 50, 1809-13	24

1995	Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes. 2011 , 131, 1300-7	65
1994	Immunologic alterations and the pathogenesis of organ failure in the ICU. 2011 , 32, 569-80	21
1993	PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. 2011 , 208, 395-407	191
1992	B7-h1 expressed by activated CD8 T cells is essential for their survival. 2011 , 187, 5606-14	48
1991	PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. 2011 , 71, 5111-22	113
1990	T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. 2011 , 17, 5736-47	32
1989	Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. 2011 , 108, 21182-7	131
1988	VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. 2011 , 208, 577-92	388
1987	Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells. 2011 , 208, 235-49	90
1986	Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. 2011 , 208, 729-45	71
1985	Host APCs augment in vivo expansion of donor natural regulatory T cells via B7H1/B7.1 in allogeneic recipients. 2011 , 186, 2739-49	40
1984	Reverse crosstalk of TGF β and PPAR γ signaling identified by transcriptional profiling. 2011 , 39, 119-31	31
1983	Prostate cancer immunotherapy. 2011 , 17, 5233-8	45
1982	Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. 2011 , 89, 507-15	75
1981	CD8 T Cells and Toxoplasma gondii: A New Paradigm. 2011 , 2011, 243796	22
1980	Blockade of B7-H1 (programmed death ligand 1) enhances humoral immunity by positively regulating the generation of T follicular helper cells. 2011 , 186, 5648-55	108
1979	The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. 2011 , 187, 1097-105	128
1978	Development and function of innate polyclonal TCR α beta $^+$ CD8 $^+$ thymocytes. 2011 , 187, 3133-44	17

1977	Hierarchical IL-5 expression defines a subpopulation of highly differentiated human Th2 cells. 2011 , 187, 3111-20	75
1976	Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. 2011 , 187, 6357-64	42
1975	NFATc1 affects mouse splenic B cell function by controlling the calcineurin--NFAT signaling network. 2011 , 208, 823-39	93
1974	Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. 2011 , 56, 118-24	67
1973	CD4 T cells promote rather than control tuberculosis in the absence of PD-1-mediated inhibition. 2011 , 186, 1598-607	211
1972	Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction. 2011 , 187, 2291-301	21
1971	Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V β V α T cells, CD8+ T cells, regulatory T cells, and dendritic cells. 2011 , 187, 1578-90	60
1970	The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. 2011 , 187, 1113-9	99
1969	Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. 2011 , 187, 1537-41	148
1968	Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. 2011 , 186, 6905-13	179
1967	Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. 2011 , 90, 77-86	15
1966	Enhancement of suboptimal CD8 cytotoxic T cell effector function in vivo using antigen-specific CD80 defective T cells. 2011 , 186, 291-304	11
1965	Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. 2011 , 17, 4232-44	262
1964	Programmed death (PD)-1-deficient mice are extremely sensitive to murine hepatitis virus strain-3 (MHV-3) infection. 2011 , 7, e1001347	31
1963	T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab. 2011 , 17, 4136-44	37
1962	Hodgkin disease and the role of the immune system. 2011 , 28, 176-86	24
1961	Immunoregulatory molecule B7-H1 (CD274) contributes to skin carcinogenesis. 2011 , 71, 4737-41	29
1960	From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors. 2011 , 2011, 439053	115

1959	Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation. 2011 , 31, 1100-7	118
1958	The role of LAT in increased CD8+ T cell exhaustion in trigeminal ganglia of mice latently infected with herpes simplex virus 1. 2011 , 85, 4184-97	87
1957	The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. 2012 , 8, e1002504	88
1956	Manipulation of costimulatory molecules by intracellular pathogens: veni, vidi, vici!! 2012 , 8, e1002676	51
1955	Loss of B7-H1 expression by recipient parenchymal cells leads to expansion of infiltrating donor CD8+ T cells and persistence of graft-versus-host disease. 2012 , 188, 724-34	24
1954	Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. 2012 , 2012, 124187	31
1953	Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. 2012 , 2012, 670957	118
1952	CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction. 2012 , 8, e1002840	108
1951	Programmed death ligand 2 in cancer-induced immune suppression. 2012 , 2012, 656340	231
1950	Coinhibitory molecules in autoimmune diseases. 2012 , 2012, 269756	34
1949	Melanoma vaccines and modulation of the immune system in the clinical setting: building from new realities. 2012 , 3, 103	5
1948	PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. 2012 , 11, 4305-9	80
1947	CD80 expression on B cells regulates murine T follicular helper development, germinal center B cell survival, and plasma cell generation. 2012 , 188, 4217-25	75
1946	CD28 ligation increases macrophage suppression of T-cell proliferation. 2012 , 9, 341-9	5
1945	Neuronal programmed cell death-1 ligand expression regulates retinal ganglion cell number in neonatal and adult mice. 2012 , 32, 227-37	7
1944	Functional interaction of CD154 protein with αE integrin is totally independent from its binding to $\alpha\text{B}\beta$ integrin and CD40 molecules. 2012 , 287, 18055-66	24
1943	Dysfunction of natural killer T cells in patients with active Mycobacterium tuberculosis infection. 2012 , 80, 2100-8	61
1942	Ataxia telangiectasia mutated kinase controls chronic gammaherpesvirus infection. 2012 , 86, 12826-37	28

1941	STATing the importance of immune modulation by platinum chemotherapeutics. 2012 , 1, 234-236	27
1940	TNF- α and TGF- β counter-regulate PD-L1 expression on monocytes in systemic lupus erythematosus. 2012 , 2, 295	51
1939	Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts. 2012 , 20, 196-203	2
1938	Tgf- β produced by activated CD4(+) T Cells Antagonizes T Cell Surveillance of Tumor Development. 2012 , 1, 162-171	31
1937	B7-H1 limits the entry of effector CD8(+) T cells to the memory pool by upregulating Bim. 2012 , 1, 1061-1073	33
1936	Cellular immune responses to hepatocellular carcinoma: lessons for immunotherapy. 2012 , 30, 483-91	30
1935	Antibodies against B7-DC with differential binding properties exert opposite effects. 2012 , 31, 40-7	5
1934	Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. 2012 , 72, 917-27	967
1933	Manipulation of CD98 resolves type 1 diabetes in nonobese diabetic mice. 2012 , 188, 2227-34	7
1932	B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. 2012 , 189, 2338-47	39
1931	IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. 2012 , 109, 12668-73	99
1930	Anti-IL-7 receptor- α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. 2012 , 109, 12674-9	95
1929	Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. 2012 , 18, 1611-8	476
1928	Activated STAT5 promotes long-lived cytotoxic CD8+ T cells that induce regression of autochthonous melanoma. 2012 , 72, 76-87	32
1927	Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. 2012 , 109, 6187-92	77
1926	Non-myeloablative transplantation of bone marrow expressing self-antigen establishes peripheral tolerance and completely prevents autoimmunity in mice. 2012 , 19, 1075-84	4
1925	Selective expansion of allogeneic regulatory T cells by hepatic stellate cells: role of endotoxin and implications for allograft tolerance. 2012 , 188, 3667-77	60
1924	Molecular action of lenalidomide in lymphocytes and hematologic malignancies. 2012 , 2012, 513702	45

1923	Strategies for enhancing vaccine-induced CTL antitumor immune responses. 2012 , 2012, 605045	13
1922	Defective CD8 T cell responses in aged mice are due to quantitative and qualitative changes in virus-specific precursors. 2012 , 188, 1933-41	86
1921	B7-H1, which represses EBV-immortalized B cell killing by autologous T and NK cells, is oppositely regulated by c-Myc and EBV latency III program at both mRNA and secretory lysosome levels. 2012 , 189, 181-90	30
1920	Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4+ T cells that mediate autoimmune-like chronic graft-versus-host disease. 2012 , 189, 222-33	67
1919	Cell-intrinsic abrogation of TGF- β signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer. 2012 , 189, 3936-46	19
1918	PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. 2012 , 188, 4876-84	163
1917	Inhibitory receptors on lymphocytes: insights from infections. 2012 , 188, 2957-65	121
1916	Mechanisms of indirect acute lung injury: a novel role for the coinhibitory receptor, programmed death-1. 2012 , 255, 158-64	39
1915	PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. 2012 , 35, 169-78	203
1914	Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. 2012 , 34, 126-8	87
1913	Vaccines for pancreatic cancer. 2012 , 18, 642-52	31
1912	Control of adaptive immune responses by Staphylococcus aureus through IL-10, PD-L1, and TLR2. 2012 , 2, 606	56
1911	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. 2012 , 120, 1412-21	264
1910	Role of the PD-1 pathway in the immune response. 2012 , 12, 2575-87	276
1909	Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. 2012 , 109, 10468-73	86
1908	Dysregulated immunophenotypic attributes of plasmacytoid but not myeloid dendritic cells in HIV-1 infected individuals in the absence of highly active anti-retroviral therapy. 2012 , 170, 212-21	16
1907	Application of monoclonal antibodies in a sandwich enzyme-linked immunosorbent assay for identification and detection of soluble human B and T lymphocyte attenuator. 2012 , 31, 417-23	3
1906	Cell biology and pathology of podocytes. 2012 , 74, 299-323	340

1905	Immunotherapy of Cancer. 2012 , 391-414	12
1904	Association of polymorphisms in non-classic MHC genes with susceptibility to autoimmune hepatitis. 2012 , 11, 125-31	22
1903	Induction and regulation of pathogenic Th17 cell responses in schistosomiasis. 2012 , 34, 873-88	44
1902	Identification of a human Th1-like IFN γ -secreting Treg subtype deriving from effector T cells. 2012 , 39, 377-87	16
1901	Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). 2012 , 10, 67-83	103
1900	Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. 2012 , 43, 132-145	7
1899	siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions. 2012 , 19, 959-66	44
1898	Emerging immunotherapies for renal cell carcinoma. 2012 , 23 Suppl 8, viii35-40	67
1897	Immunotherapy earns its spot in the ranks of cancer therapy. 2012 , 209, 201-9	108
1896	Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. 2012 , 209, 1201-17	610
1895	What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?. 2012 , 23 Suppl 8, viii28-34	35
1894	Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. 2012 , 109, 15419-24	67
1893	IL-2-engineered nano-APC effectively activates viral antigen-mediated T cell responses from chronic hepatitis B virus-infected patients. 2012 , 188, 1534-43	6
1892	Peginterferon- α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. 2012 , 56, 1239-46	58
1891	Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. 2012 , 36, 477-90	150
1890	Tuberculosis vaccine development: strength lies in tenacity. 2012 , 33, 373-9	59
1889	Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. 2012 , 24, 207-12	979
1888	Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections. 2012 , 56, 1567-74	97

1887	Increased bovine Tim-3 and its ligand expressions during bovine leukemia virus infection. 2012 , 43, 45	19
1886	Humoral and cellular immune responses after influenza vaccination in patients with chronic fatigue syndrome. 2012 , 13, 71	9
1885	Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011. 2012 , 10, 108	10
1884	IL-1 signal affects both protection and pathogenesis of virus-induced chronic CNS demyelinating disease. 2012 , 9, 217	38
1883	Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus. 2012 , 9, 94	14
1882	Plasmacytoid dendritic cells are inefficient in activation of human regulatory T cells. 2012 , 7, e44056	7
1881	IL-10 controls dendritic cell-induced T-cell reactivation in the skin to limit contact hypersensitivity. 2012 , 129, 143-50.e1-10	41
1880	The myeloid cytokine network in AIDS pathogenesis. 2012 , 23, 223-31	9
1879	Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. 2012 , 53, 2015-23	33
1878	Klf4 regulates the expression of Slurp1, which functions as an immunomodulatory peptide in the mouse cornea. 2012 , 53, 8433-46	29
1877	Adoptive immunotherapy of advanced melanoma. 2012 , 13, 340-53	11
1876	Evolution of cellular immunotherapy: from allogeneic transplant to dendritic cell vaccination as treatment for multiple myeloma. 2012 , 4, 1043-51	8
1875	Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. 2012 , 188, 1136-46	157
1874	The genetics of Behçet's disease in a Chinese population. 2012 , 6, 354-9	15
1873	Control of Innate and Adaptive Immune Responses during Infectious Diseases. 2012 ,	1
1872	Kidney Cancer. 2012 ,	4
1871	Innate Immune Regulation and Cancer Immunotherapy. 2012 ,	3
1870	Blocking of PDL-1 interaction enhances primary and secondary CD8 T cell response to herpes simplex virus-1 infection. 2012 , 7, e39757	35

1869	Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN- γ -producing T cells. 2012 , 7, e44728	72
1868	Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. 2012 , 7, e45272	134
1867	The role of coinhibitory signaling pathways in transplantation and tolerance. 2012 , 3, 47	47
1866	Multiple mechanisms of immune suppression by B lymphocytes. 2012 , 18, 123-37	99
1865	Combining immunotherapy and targeted therapies in cancer treatment. 2012 , 12, 237-51	1007
1864	The blockade of immune checkpoints in cancer immunotherapy. 2012 , 12, 252-64	8091
1863	Cellular teamwork in antibacterial innate immunity. 2012 , 13, 115-7	7
1862	Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. 2012 , 120, 728-36	59
1861	Study of CD4+CD8+ double positive T-lymphocyte phenotype and function in Indian patients infected with HIV-1. 2012 , 84, 845-56	14
1860	Blockade of Tim-3 signaling restores the virus-specific CD8+ T-cell response in patients with chronic hepatitis B. 2012 , 42, 1180-91	118
1859	Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8+ T cells. 2012 , 42, 662-71	13
1858	PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease. 2012 , 130, 2327-36	27
1857	State of the science: an update on renal cell carcinoma. 2012 , 10, 859-80	121
1856	T-cell tolerance: central and peripheral. 2012 , 4,	241
1855	A new therapeutic strategy for malaria: targeting T cell exhaustion. 2012 , 13, 113-5	22
1854	The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. 2012 , 3, 441-9	5
1853	The battle against immunopathology: infectious tolerance mediated by regulatory T cells. 2012 , 69, 1997-2008	56
1852	Role of PD-1 in HIV pathogenesis and as target for therapy. 2012 , 9, 81-90	99

1851	Evolution of the B7 family: co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC. 2012 , 64, 571-90	61
1850	The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues. 2012 , 61, 1101-11	33
1849	Effects of antiviral therapy with Telbivudine on peripheral iNKT cells in HBeAg(+) chronic hepatitis B patients. 2012 , 12, 105-13	18
1848	Potential role of soluble B7-H3 in liver immunopathogenesis during chronic HBV infection. 2012 , 19, 23-31	9
1847	Experimental mouse tumour models: what can be learnt about human cancer immunology?. 2011 , 12, 61-6	85
1846	IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction--a comparative study of human clinical-applicable DC. 2012 , 142, 332-42	180
1845	Immuno-inhibitory PD-L1 can be induced by a peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations. 2012 , 143, 162-9	20
1844	Program death-1 regulates peripheral T cell tolerance via an energy-independent mechanism. 2012 , 143, 128-33	10
1843	Genes, tolerance and systemic autoimmunity. 2012 , 11, 664-9	29
1842	Dendritic/tumor fusion cells as cancer vaccines. 2012 , 39, 287-95	30
1841	The role of costimulatory molecules in directing the functional differentiation of alloreactive T helper cells. 2012 , 12, 2588-600	25
1840	The B7 homologues and their receptors in hematologic malignancies. 2012 , 88, 465-75	13
1839	Roles of BCL6 in normal and transformed germinal center B cells. 2012 , 247, 172-83	267
1838	Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels. 2012 , 169, 263-72	38
1837	Therapy for metastatic melanoma: the past, present, and future. 2012 , 10, 23	144
1836	Identification of a microglia phenotype supportive of remyelination. 2012 , 60, 306-21	247
1835	Blockade of bovine PD-1 increases T cell function and inhibits bovine leukemia virus expression in B cells in vitro. 2013 , 44, 59	39
1834	Combination checkpoint blockade--taking melanoma immunotherapy to the next level. 2013 , 369, 187-9	61

1833	Expression and significance of B7-H1 in peripheral blood dendritic cells from patients with bladder cancer. 2013 , 12, 290-292	
1832	Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. 2013 , 17, R85	171
1831	Cancer Immunotherapy. 2013 ,	1
1830	Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. 2013 , 62, 839-49	18
1829	B7 family checkpoint regulators in immune regulation and disease. 2013 , 34, 556-63	212
1828	In Vitro Treatment with Ganciclovir Restores the Functionality of Exhausted T Cells from Cancer Patients. 2013 , 7, 171-176	2
1827	Genetic variations of immunoregulatory genes associated with Rasmussen syndrome. 2013 , 107, 238-43	7
1826	Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. 2013 , 19, 4917-24	202
1825	Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. 2013 , 73, 3591-603	475
1824	Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. 2013 , 31, 4199-206	384
1823	Psychiatric disorders in toxoplasma seropositive patients--the CD8 connection. 2013 , 39, 485-9	29
1822	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. 2013 , 14, 1212-8	611
1821	PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. 2013 , 19, 3462-73	601
1820	Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. 2013 , 19, 3640-8	167
1819	Abatacept in B7-1-positive proteinuric kidney disease. 2013 , 369, 2416-23	281
1818	Fas signal promotes the immunosuppressive function of regulatory dendritic cells via the ERK/Eatenin pathway. 2013 , 288, 27825-35	30
1817	Apoptotic cell administration enhances pancreatic islet engraftment by induction of regulatory T cells and tolerogenic dendritic cells. 2013 , 10, 393-402	25
1816	Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. 2013 , 31, 4268-70	11

1815	Autoimmune effector memory T cells: the bad and the good. 2013 , 57, 12-22	62
1814	Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. 2013 , 190, 5620-8	81
1813	Rapid deletion and inactivation of CTLs upon recognition of a number of target cells over a critical threshold. 2013 , 191, 3534-44	11
1812	Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity. 2013 , 191, 4121-9	70
1811	Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. 2013 , 122, 394-404	100
1810	Antibody therapeutics in cancer. 2013 , 341, 1192-8	412
1809	CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. 2013 , 19, 5300-9	485
1808	The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. 2013 , 6, 74	176
1807	PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. 2013 , 10, 111	42
1806	Peripheral CD45RO, PD-1, and TLR4 expression in metastatic colorectal cancer patients treated with bevacizumab, fluorouracil, and irinotecan (FOLFIRI-B). 2013 , 30, 743	14
1805	Transcriptional profiling of feline infectious peritonitis virus infection in CRFK cells and in PBMCs from FIP diagnosed cats. 2013 , 10, 329	14
1804	Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. 2013 , 39, 758-69	613
1803	Advances in the development of cancer immunotherapies. 2013 , 34, 90-8	34
1802	Immunotherapy at large: Balancing tumor immunity and inflammatory pathology. 2013 , 19, 1100-1	24
1801	Cancer immunotherapy: current status and future directions. 2013 , 22, 765-83	18
1800	Systemic minor histocompatibility antigen expression in blood endothelial cells prevents T cell-mediated vascular immunopathology. 2013 , 43, 3233-43	
1799	Systems Biology of Tumor Dormancy. 2013 ,	6
1798	Confounding roles for type I interferons during bacterial and viral pathogenesis. 2013 , 25, 663-9	33

1797	Harnessing the power of the immune system to target cancer. 2013 , 64, 71-90	103
1796	Enhanced expression of LAG-3 on lymphocyte subpopulations from persistently lymphocytotic cattle infected with bovine leukemia virus. 2013 , 36, 63-9	17
1795	Allogenicity of human cardiac stem/progenitor cells orchestrated by programmed death ligand 1. 2013 , 112, 451-64	60
1794	Role of TLR2-dependent IL-10 production in the inhibition of the initial IFN- γ cell response to <i>Porphyromonas gingivalis</i> . 2013 , 93, 21-31	40
1793	Tumor dormancy: long-term survival in a hostile environment. 2013 , 734, 181-200	10
1792	Immune Co-signaling to Treat Cancer. 2013 , 211-280	1
1791	Intrahepatic expression of programmed death-1 and its ligands in patients with HBV-related acute-on-chronic liver failure. 2013 , 36, 110-20	24
1790	Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. 2013 , 19, 1661-9	13
1789	Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis. 2013 , 256, 55-61	78
1788	In vivo blockade of the programmed cell death-1 pathway using soluble recombinant PD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit. 2013 , 191, 6060-70	48
1787	The heart of the matter: protection of the myocardium from T cells. 2013 , 45, 90-6	47
1786	[Immunological analogies between ovarian cancer and pregnancy]. 2013 , 42, 217-26	
1785	An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules. 2013 , 74, 1103-10	6
1784	Programmed cell death ligand 2 regulates TH9 differentiation and induction of chronic airway hyperreactivity. 2013 , 131, 1048-57, 1057.e1-2	71
1783	Translational research in melanoma. 2013 , 22, 785-804	
1782	Adenovirus expressing both thymidine kinase and soluble PD1 enhances antitumor immunity by strengthening CD8 T-cell response. 2013 , 21, 688-95	44
1781	Adaptive immune responses in hepatitis C virus infection. 2013 , 369, 243-62	45
1780	Myeloid leukemia cells with a B7-2(+) subpopulation provoke Th-cell responses and become immuno-suppressive through the modulation of B7 ligands. 2013 , 43, 747-57	40

1779	Molecular mechanisms of T cell co-stimulation and co-inhibition. 2013 , 13, 227-42	1711
1778	The immune response in tuberculosis. <i>Annual Review of Immunology</i> , 2013 , 31, 475-527	34.7 823
1777	Endocrine side effects induced by immune checkpoint inhibitors. 2013 , 98, 1361-75	299
1776	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. 2013 , 13, 847-61	96
1775	Coinhibitory molecules in cancer biology and therapy. 2013 , 24, 147-61	24
1774	PD-1 coinhibitory signals: the link between pathogenesis and protection. 2013 , 25, 219-27	44
1773	At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. 2013 , 94, 25-39	266
1772	The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. 2013 , 34, 193-9	15
1771	Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. 2013 , 13, 260-8	899
1770	In vivo imaging of graft-versus-host disease and graft-versus-leukemia. 2013 , 59-81	
1769	Pharmacotherapy of metastatic melanoma: emerging trends and opportunities for a cure. 2013 , 139, 405-11	11
1768	Immune privilege of stem cells. 2013 , 1029, 1-16	12
1767	Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. 2013 , 162, 313-25	76
1766	Lack of association between CTLA-4 and PDCD1 polymorphisms and acute rejection in German liver transplant recipients. 2013 , 74, 1041-5	3
1765	A novel tylophorine analog W-8 up-regulates forkhead boxP3 expression and ameliorates murine colitis. 2013 , 93, 83-93	9
1764	Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC). 2013 , 94, 1201-6	8
1763	Tuberculosis vaccines: time to think about the next generation. 2013 , 25, 172-81	103
1762	Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. 2013 , 94, 963-70	35

1761	The Tumor Immunoenvironment. 2013,	3
1760	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. 2013, 49, 2233-42	319
1759	Manipulating the PD-1 pathway to improve immunity. 2013, 25, 381-8	75
1758	Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. 2013, 19, 6151-62	80
1757	Toxoplasma gondii rhoptry 16 kinase promotes host resistance to oral infection and intestinal inflammation only in the context of the dense granule protein GRA15. 2013, 81, 2156-67	64
1756	Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. 2013, 191, 1011-5	55
1755	The role of interleukin-6 in the expression of PD-1 and PDL-1 on central nervous system cells following infection with Theiler's murine encephalomyelitis virus. 2013, 87, 11538-51	26
1754	Recent advances in the treatment of metastatic renal cell carcinoma. 2013, 20, 944-55	44
1753	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. 2013, 12, 597-615	49
1752	CD4 T-cell immunotherapy for chronic viral infections and cancer. 2013, 5, 975-87	43
1751	Histone methyltransferase and histone methylation in inflammatory T-cell responses. 2013, 5, 989-1004	27
1750	PD-L1 blockade attenuated sepsis-induced liver injury in a mouse cecal ligation and puncture model. 2013, 2013, 361501	33
1749	PD-1 and CTLA-4 Mediated Inhibitory Signaling for T cell Exhaustion during Chronic Viral Infections. 2013, 01,	2
1748	Biologics in dermatology. 2013, 6, 557-78	7
1747	Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN- γ -mediated CD8(+) T cell cytotoxicity. 2013, 35, 623-31	34
1746	Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection. 2013, 9, e1003215	44
1745	Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. 2013, 208, 50-6	176
1744	Immune activation and HIV persistence: considerations for novel therapeutic interventions. 2013, 8, 211-6	57

1743	Cancer vaccines: Looking to the future. 2013 , 2, e23403	45
1742	Strength of PD-1 signaling differentially affects T-cell effector functions. 2013 , 110, E2480-9	192
1741	Tumor immunology: multidisciplinary science driving basic and clinical advances. 2013 , 1, 16-23	5
1740	Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. 2013 , 19, 1021-34	381
1739	Human plasmacytoid dendritic cells: from molecules to intercellular communication network. 2013 , 4, 372	60
1738	PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. 2013 , 123, 2604-15	174
1737	Recipient myeloid-derived immunomodulatory cells induce PD-1 ligand-dependent donor CD4+Foxp3+ regulatory T cell proliferation and donor-recipient immune tolerance after murine nonmyeloablative bone marrow transplantation. 2013 , 191, 5764-76	25
1736	Batf3-dependent dendritic cells in the renal lymph node induce tolerance against circulating antigens. 2013 , 24, 543-9	29
1735	Update on the use of transgenic rice seeds in oral immunotherapy. 2013 , 5, 301-12	30
1734	Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. 2013 , 73, 6900-12	207
1733	PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. 2013 , 210, 757-74	169
1732	Immunosuppressive microenvironment in neuroblastoma. 2013 , 3, 167	49
1731	Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies. 2013 , 4, 221	31
1730	Programmed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function. 2013 , 78, 239-247	29
1729	Latest approved therapies for metastatic melanoma: what comes next?. 2013 , 2013, 735282	22
1728	Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease. 2013 , 190, 5402-10	45
1727	Constitutively CD40-activated B cells regulate CD8 T cell inflammatory response by IL-10 induction. 2013 , 190, 3189-96	8
1726	A co-stimulatory trap set by myeloid leukemia cells. 2013 , 2, e24524	3

1725	Costimulatory molecules on immunogenic versus tolerogenic human dendritic cells. 2013 , 4, 82	136
1724	Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?. 2013 , 26, 167-75	9
1723	Characterization of regulatory dendritic cells differentiated from the bone marrow of UV-irradiated mice. 2013 , 140, 399-412	15
1722	Identification and quantification of total coumarins from <i>Urtica dentata</i> Hand and its roles in promoting immune tolerance via TLR4-mediated dendritic cell immaturation. 2013 , 77, 1200-6	7
1721	Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. 2013 , 107, 517-22	64
1720	PD-1 as a potential target in cancer therapy. 2013 , 2, 662-73	306
1719	Insights into the role of Bcl6 in follicular Th cells using a new conditional mutant mouse model. 2013 , 191, 3705-11	85
1718	Structure and interactions of the human programmed cell death 1 receptor. 2013 , 288, 11771-85	185
1717	Comparison of induced versus natural regulatory T cells of the same TCR specificity for induction of tolerance to an environmental antigen. 2013 , 191, 1136-43	32
1716	A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. 2013 , 191, 2205-16	69
1715	PD-L1/B7-H1 regulates the survival but not the function of CD8+ T cells in herpes simplex virus type 1 latently infected trigeminal ganglia. 2013 , 190, 6277-86	21
1714	Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. 2013 , 19, 5636-46	485
1713	High-avidity T cells are preferentially tolerized in the tumor microenvironment. 2013 , 73, 595-604	33
1712	Inhibiting the inhibitors: Checkpoints blockade in solid tumors. 2013 , 2, e26535	15
1711	Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. 2013 , 122, 3062-73	141
1710	A grim picture, indeed. 2013 , 41, 923-4	
1709	The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells. 2013 , 13, 68-79	16
1708	[Influence of PD-1 on the immunological synapse: a facet of immune regulation ?]. 2013 , 29, 1080-2	1

1707	Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. 2013 , 123, 1677-93	53
1706	Clonal expansions of CD8+ T cells with IL-10 secreting capacity occur during chronic Mycobacterium tuberculosis infection. 2013 , 8, e58612	28
1705	The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease. 2013 , 8, e60367	11
1704	NF- κ B plays a key role in inducing CD274 expression in human monocytes after lipopolysaccharide treatment. 2013 , 8, e61602	54
1703	PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. 2013 , 8, e65821	173
1702	A missing PD-L1/PD-1 coinhibition regulates diabetes induction by preproinsulin-specific CD8 T-cells in an epitope-specific manner. 2013 , 8, e71746	5
1701	Characterization of regulatory dendritic cells that mitigate acute graft-versus-host disease in older mice following allogeneic bone marrow transplantation. 2013 , 8, e75158	10
1700	B7-H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. 2013 , 8, e76012	116
1699	TLR2 directing PD-L2 expression inhibit T cells response in Schistosoma japonicum infection. 2013 , 8, e82480	17
1698	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. 2013 , 4, 417	53
1697	Transplant tolerance: new insights and strategies for long-term allograft acceptance. 2013 , 2013, 210506	30
1696	PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response. 2013 , 2013, 989673	19
1695	Emerging Co-signaling Networks in T Cell Immune Regulation. 2013 , 13, 184-93	40
1694	ALK: Anaplastic lymphoma kinase. 162-189	0
1693	Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights. 2014 , 1	1
1692	Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. 2014 , 6, 279-89	17
1691	Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. 2014 , 7, 567-73	172
1690	Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. 2014 , 9, e93280	59

1689	Bystander activation and anti-tumor effects of CD8+ T cells following Interleukin-2 based immunotherapy is independent of CD4+ T cell help. 2014 , 9, e102709	20
1688	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. 2014 , 8, 228	9
1687	Corneal Lymphatics: Role in Ocular Inflammation as Inducer and Responder of Adaptive Immunity. 2014 , 5,	35
1686	Overexpression of herpes simplex virus glycoprotein K (gK) alters expression of HSV receptors in ocularly-infected mice. 2014 , 55, 2442-51	16
1685	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation. 2014 ,	3
1684	Inhibitory receptor-mediated regulation of natural killer cells. 2014 , 34, 455-65	5
1683	Pidilizumab in the treatment of diffuse large B-cell lymphoma. 2014 , 14, 1361-8	19
1682	Out of the bitter came forth sweet: Activating CD28-dependent co-stimulation via PD-1 ligands. 2014 , 3, e27399	15
1681	The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?. 2014 , 5, 45-56	181
1680	Adaptor protein DOK3 promotes plasma cell differentiation by regulating the expression of programmed cell death 1 ligands. 2014 , 111, 11431-6	15
1679	PD-1 and PD-L1 antibodies for melanoma. 2014 , 10, 3111-6	41
1678	Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. 2014 , 193, 2565-73	54
1677	New antibody approaches to lymphoma therapy. 2014 , 7, 58	44
1676	Toso controls encephalitogenic immune responses by dendritic cells and regulatory T cells. 2014 , 111, 1060-5	36
1675	Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. 2014 , 16, 469	42
1674	PD-1 is not required for natural or peripherally induced regulatory T cells: Severe autoimmunity despite normal production of regulatory T cells. 2014 , 44, 3560-72	27
1673	Mucosal-associated invariant T cell deficiency in systemic lupus erythematosus. 2014 , 193, 3891-901	117
1672	CD271 on melanoma cell is an IFN- γ -inducible immunosuppressive factor that mediates downregulation of melanoma antigens. 2014 , 134, 1369-1377	41

1671	Immunological Tolerance. 2014 ,	3
1670	The Duality of Fgl2 - Secreted Immune Checkpoint Regulator Versus Membrane-Associated Procoagulant: Therapeutic Potential and Implications. 2016 , 35, 325-339	32
1669	Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?. 2014 , 6, 1180-94	8
1668	Functional Signatures of Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis. 2014 , 5, 180	152
1667	A Promoter Region Polymorphism in PDCD-1 Gene Is Associated with Risk of Rheumatoid Arthritis in the Han Chinese Population of Southeastern China. 2014 , 2014, 247637	22
1666	Immunotherapy for Lung Cancer: Has it Finally Arrived?. 2014 , 4, 288	28
1665	Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. 2014 , 10, e1003993	164
1664	Malaria drives T cells to exhaustion. 2014 , 5, 249	50
1663	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. 2014 , 3, 443-457	7
1662	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. 2014 , 3, 175-190	1
1661	Targeting CD28 to prevent transplant rejection. 2014 , 18, 225-42	8
1660	The adaptation model of immunity. 2014 , 6, 59-70	8
1659	The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond. 2014 , 46, 384-96	12
1658	Steady-state antigen scavenging, cross-presentation, and CD8+ T cell priming: a new role for lymphatic endothelial cells. 2014 , 192, 5002-11	135
1657	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. 2014 , 28, 2367-75	239
1656	The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease. 2014 , 24, 953-60	8
1655	Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. 2014 , 29, 153-61	60
1654	Identification and characterization of bovine programmed death-ligand 2. 2014 , 58, 388-97	1

1653	Nano-Oncologicals. 2014,	4
1652	The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. 2014, 41, 802-14	218
1651	Tobacco exposure and susceptibility to tuberculosis: is there a smoking gun?. 2014, 94, 544-50	27
1650	Preparing for tomorrow: molecular diagnostics and the changing nonsmall cell lung cancer landscape. 2014, 10 Suppl 2, 2-10	3
1649	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. 2014, 515, 577-81	1331
1648	The mitochondrial protein TCAIM regulates activation of T cells and thereby promotes tolerance induction of allogeneic transplants. 2014, 14, 2723-35	8
1647	Therapeutic immunization and local low-dose tumor irradiation, a reinforcing combination. 2014, 134, 859-72	35
1646	Requirement for interactions of natural killer T cells and myeloid-derived suppressor cells for transplantation tolerance. 2014, 14, 2467-77	49
1645	Negative role of inducible PD-1 on survival of activated dendritic cells. 2014, 95, 621-9	30
1644	Abatacept in B7-1-positive proteinuric kidney disease. 2014, 370, 1263-6	65
1643	Biology and treatment of myeloma. 2014, 14 Suppl, S65-70	13
1642	Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. 2014, 28, 513-26	7
1641	Negative Immunomodulators [Blunting Immunostimulation and Facilitating Infection. 2014,	
1640	Antigen-dependent integration of opposing proximal TCR-signaling cascades determines the functional fate of T lymphocytes. 2014, 192, 2109-19	24
1639	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. 2014, 10, 79-90	21
1638	Failure to upregulate cell surface PD-1 is associated with dysregulated stimulation of T cells by TGN1412-like CD28 superagonist. 2014, 6, 1290-9	7
1637	Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. 2014, 43, 101-8	59
1636	Biochemical signaling of PD-1 on T cells and its functional implications. 2014, 20, 265-71	112

1635	The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. 2014 , 26, 204-14	57
1634	Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. 2014 , 20, 256-61	96
1633	Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. 2014 , 38, 1715-23	117
1632	Dendritic cell cancer vaccines: from the bench to the bedside. 2014 , 5, e0024	9
1631	HIV-1 Tat protein induces PD-L1 (B7-H1) expression on dendritic cells through tumor necrosis factor alpha- and toll-like receptor 4-mediated mechanisms. 2014 , 88, 6672-89	39
1630	Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy. 2014 , 5, 74	34
1629	Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. 2014 , 2, 643-54	190
1628	Tfh cell differentiation and their function in promoting B-cell responses. 2014 , 841, 153-80	8
1627	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors. 2014 , 143-205	2
1626	Impaired selectin-dependent leukocyte recruitment induces T-cell exhaustion and prevents chronic allograft vasculopathy and rejection. 2014 , 111, 12145-50	30
1625	Expression of programmed death-1 (PD-1) on CD4+ and CD8+ T cells in rheumatoid arthritis. 2014 , 37, 116-21	45
1624	Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. 2014 , 15, 69-77	441
1623	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. 2014 , 50, 1361-9	241
1622	Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. 2014 , 47, 612-7	32
1621	A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. 2014 , 40, 105-16	79
1620	Phagocytes and Immunoglobulins. 2014 , 95-113	1
1619	CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis. 2014 , 11, 18	18
1618	Comparison of dynamic expressions of Tim-3 and PD-1 in the brains between toxoplasmic encephalitis-resistant BALB/c and -susceptible C57BL/6 mice. 2014 , 113, 1261-7	6

1617 Impfung gegen Tuberkulose. **2014**, 11, 42-52

1616 Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. **2014**, 18, R3 177

1615 CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. **2014**, 2, 91-8 199

1614 The complex and central role of interferon- γ in graft-versus-host disease and graft-versus-tumor activity. **2014**, 258, 30-44 40

1613 Immunomodulation of mesenchymal stromal cells on regulatory T cells and its possible mechanism. **2014**, 324, 65-74 65

1612 Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. **2014**, 89, 140-65 122

1611 Orchestrating immune check-point blockade for cancer immunotherapy in combinations. **2014**, 27, 89-97 90

1610 Inhibition of TNF receptor signaling by anti-TNF β biologicals primes naïve CD4(+) T cells towards IL-10(+) T cells with a regulatory phenotype and function. **2014**, 151, 136-45 16

1609 Identification of B7-H1 as a novel mediator of the innate immune/proinflammatory response as well as a possible myeloid cell prognostic biomarker in sepsis. **2014**, 192, 1091-9 41

1608 Molecules in medicine mini review: the T cell receptor. **2014**, 92, 735-41 20

1607 Interaction of Immune and Cancer Cells. **2014**,

1606 Follicular T-helper cells: controlled localization and cellular interactions. **2014**, 92, 28-33 20

1605 Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. **2014**, 28, 993-1000 81

1604 Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. **2014**, 21, 262-71 62

1603 An effective approach to prevent immune rejection of human ESC-derived allografts. **2014**, 14, 121-30 164

1602 Influence of PD-L1 cross-linking on cell death in PD-L1-expressing cell lines and bovine lymphocytes. **2014**, 142, 551-61 34

1601 Tolerance and exhaustion: defining mechanisms of T cell dysfunction. **2014**, 35, 51-60 380

1600 Natural killer T cell energy, co-stimulatory molecules and immunotherapeutic interventions. **2014**, 75, 250-60 29

1599	T Lymphocytes as Tools in Diagnostics and Immunotoxicology. 2014,	1
1598	Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. 2014, 28, 1280-8	460
1597	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. 2014, 11, 24-37	311
1596	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. 2014, 18, 1407-20	28
1595	Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. 2014, 92, 195-203	79
1594	Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. 2014, 134, 319-31	87
1593	Current perspectives on immunotherapy. 2014, 41 Suppl 5, S14-29	23
1592	Mechanism of action of immunotherapy. 2014, 41 Suppl 5, S3-13	89
1591	Design and development of therapies using chimeric antigen receptor-expressing T cells. 2014, 257, 107-26	338
1590	The path to reactivation of antitumor immunity and checkpoint immunotherapy. 2014, 2, 926-36	22
1589	Immunotherapy advances for glioblastoma. 2014, 16, 1441-58	136
1588	PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. 2014, 111, 1391-9	68
1587	Antibody-based immunotherapy for malignant glioma. 2014, 41, 496-510	11
1586	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. 2014, 384, 1109-17	1340
1585	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. 2014, 14, 1173-87	23
1584	Immune modulation for cancer therapy. 2014, 111, 2214-9	110
1583	T Helper Cell Differentiation and Their Function. 2014,	5
1582	No longer an untreatable disease: how targeted and immunotherapies have changed the management of melanoma patients. 2014, 8, 1140-58	39

1581	Management of Castration Resistant Prostate Cancer. 2014,	0
1580	Telomere shortening and immune activity in war veterans with posttraumatic stress disorder. 2014, 54, 275-83	48
1579	Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis. 2014, 143, 319-30	13
1578	Non-small-cell lung cancers: a heterogeneous set of diseases. 2014, 14, 535-46	934
1577	PD-1 regulates extrathymic regulatory T-cell differentiation. 2014, 44, 2603-16	68
1576	Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases. 2014,	3
1575	Transplanted terminally differentiated induced pluripotent stem cells are accepted by immune mechanisms similar to self-tolerance. 2014, 5, 3903	127
1574	The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. 2014, 193, 3835-41	127
1573	Testicular defense systems: immune privilege and innate immunity. 2014, 11, 428-37	153
1572	CD160 isoforms and regulation of CD4 and CD8 T-cell responses. 2014, 12, 217	16
1571	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. 2014, 211, 1905-18	151
1570	Multiple Sclerosis. 2014, 393-412	
1569	PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. 2014, 63, 395-406	111
1568	B7-H1 signaling is integrated during CD8(+) T cell priming and restrains effector differentiation. 2014, 63, 859-67	11
1567	Expression analysis of programmed death ligand 2 in tumors caused by the avian oncovirus Marek's disease virus. 2014, 159, 2123-6	2
1566	T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. 2014, 145, 605-14	19
1565	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. 2014, 146, 15-24	375
1564	Diffuse large B-cell lymphoma-treatment approaches in the molecular era. 2014, 11, 12-23	274

1563	Immunotherapy for lung cancer: ongoing clinical trials. 2014 , 10, 91-105	21
1562	Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. 2014 , 31, 960	16
1561	Programmed death 1 deficiency induces the polarization of macrophages/microglia to the M1 phenotype after spinal cord injury in mice. 2014 , 11, 636-50	73
1560	Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. 2014 , 12, 119	16
1559	The role of the adaptive immune system in regulation of gut microbiota. 2014 , 260, 67-75	86
1558	Immunologic and clinical effects of targeting PD-1 in lung cancer. 2014 , 96, 214-23	62
1557	Microglia in Health and Disease. 2014 ,	9
1556	Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease. 2014 , 274, 78-85	12
1555	Up-regulated expression of PD-1 and its ligands during acute Classical Swine Fever virus infection in swine. 2014 , 97, 251-6	9
1554	Mesenchymal stem cells suppress T cells by inducing apoptosis and through PD-1/B7-H1 interactions. 2014 , 162, 248-55	40
1553	In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. 2014 , 20, 2773-82	337
1552	RGMB is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. 2014 , 211, 943-59	182
1551	Immunotherapy in the treatment of non-small cell lung cancer. 2014 , 85, 101-9	95
1550	PD-1/PD-Ls pathways between CD4(+) T cells and pleural mesothelial cells in human tuberculous pleurisy. 2014 , 94, 131-9	9
1549	The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. 2014 , 50, 627-32	161
1548	Tissue-expressed B7-H1 critically controls intestinal inflammation. 2014 , 6, 625-32	36
1547	Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy. 2014 , 2, 538-46	26
1546	Gut TFH and IgA: key players for regulation of bacterial communities and immune homeostasis. 2014 , 92, 49-56	64

1545	Current Advances in Osteosarcoma. 2014 ,	7
1544	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. 2014 , 14, 1007-17	7
1543	The PD-1/PD-Ls pathway and autoimmune diseases. 2014 , 290, 72-9	215
1542	Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors. 2014 , 24, 3403-6	41
1541	Immune checkpoint blockade. 2014 , 28, 585-600	57
1540	Role of immunotherapy in castration-resistant prostate cancer (CRPC). 2014 , 113, 367-75	3
1539	Changes in the PD-1 and PD-L1 expressions of splenic dendritic cells in multiple-organ dysfunction syndrome mice and their significance. 2014 , 13, 7666-72	8
1538	Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic polymorphism rs11568821. 2014 , 62, 638-43	18
1537	PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. 2014 , 21, 231-7	104
1536	Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. 2014 , 124, 2858-66	44
1535	Small Animal Models of Transplantation. 2014 , 158-184	2
1534	PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. 2014 , 30, 761-6	32
1533	Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. 2014 ,	1
1532	Interleukin-25 Mediates Transcriptional Control of PD-L1 via STAT3 in Multipotent Human Mesenchymal Stromal Cells (hMSCs) to Suppress Th17 Responses. 2015 , 5, 392-404	46
1531	Immune Cell Identity: Perspective from a Palimpsest. 2015 , 58, 205-28	1
1530	Dysregulated co-stimulatory molecule expression in a Sjögren's syndrome mouse model with potential implications by microRNA-146a. 2015 , 68, 606-16	9
1529	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. 2015 , 10, 1726-35	155
1528	Regulation of B Cell to Plasma Cell Transition within the Follicular B Cell Response. 2015 , 82, 225-34	20

1527	Functional Mechanism(s) of the Inhibition of Disease Progression by Combination Treatment with Fingolimod Plus Pathogenic Antigen in a Glucose-6-phosphate Isomerase Peptide-Induced Arthritis Mouse Model. 2015 , 38, 1120-5	3
1526	Decreased programmed death-1 expression on the T cells of patients with ankylosing spondylitis. 2015 , 349, 488-92	9
1525	Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. 2015 , 5, 13110	246
1524	Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. 2015 , 126, 2193-201	312
1523	Cell-specific PD-L1 expression in DLBCL. 2015 , 126, 2171-2	10
1522	Biologic agents in the management of Hodgkin lymphoma. 2015 , 13, 587-96	4
1521	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. 2015 , 7, 15-8	42
1520	Biomarkers for Sepsis: What Is and What Might Be?. 2015 , 10, 7-17	73
1519	Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?. 2015 , 25, 461-9	18
1518	Emerging immunotherapies for bladder cancer. 2015 , 27, 191-200	21
1517	Primary malignant mucosal melanoma of the upper lip: a case report and review of the literature. 2015 , 8, 499	14
1516	Inhibitory receptors as targets for cancer immunotherapy. 2015 , 45, 1892-905	84
1515	Histopathological and immunophenotypical criteria for the diagnosis of Sezary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force Study of 97 cases. 2015 , 173, 93-105	44
1514	Up-regulation of programmed cell death 1 ligand 1 on neutrophils may be involved in sepsis-induced immunosuppression: an animal study and a prospective case-control study. 2015 , 122, 852-63	60
1513	Immunotherapy for Advanced Lung Cancer. 2015 , 21, 383-91	6
1512	Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. 2015 , 27, 384-91	15
1511	Injectable, Pore-Forming Hydrogels for In Vivo Enrichment of Immature Dendritic Cells. 2015 , 4, 2677-87	61
1510	Targeting immune checkpoints in lymphoma. 2015 , 22, 337-42	31

1509	Modeling idiosyncrasy: a novel animal model of drug-induced liver injury. 2015 , 61, 1124-6	5
1508	Programmed death 1 and its ligands do not limit experimental foreign antigen-induced immune complex glomerulonephritis. 2015 , 20, 892-8	4
1507	Immunotherapies for bladder cancer: a new hope. 2015 , 25, 586-96	13
1506	Interleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression. 2015 , 43, 334-43	65
1505	Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. 2015 , e291-7	4
1504	Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. 2015 , 6, 41228-36	140
1503	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. 2015 , 5,	
1502	Biomarkers of Response to Immune Modulatory Therapies in Cancer. 2015 , 06,	
1501	Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down. 2015 , 9, 2-14	11
1500	New developments in the management of advanced melanoma - role of pembrolizumab. 2015 , 8, 2535-43	13
1499	Immunity, inflammation, and cancer: an eternal fight between good and evil. 2015 , 125, 3347-55	423
1498	New and promising strategies in the management of bladder cancer. 2015 , 105-12	14
1497	Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment. 2015 , 2, 4-15	
1496	Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. 2015 , 15, 16281-313	100
1495	Enhancing Human Immunodeficiency Virus-Specific CD8(+) T Cell Responses with Heteroclitic Peptides. 2015 , 6, 377	6
1494	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications. 2015 , 6, 505	71
1493	Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. 2015 , 6, 601	105
1492	T Lymphocyte-Endothelial Interactions: Emerging Understanding of Trafficking and Antigen-Specific Immunity. 2015 , 6, 603	96

1491	Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. 2015 , 5, 153	98
1490	The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. 2015 , 6, 14209-19	156
1489	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. 2015 , 7, 5889-901	15
1488	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. 2015 , 6, 7-17	48
1487	Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. 2015 , 3, 771-802	9
1486	Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. 2015 , 8, 1451-7	24
1485	Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment. 2015 , 10, e0119483	31
1484	Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF- κ B. 2015 , 10, e0123410	145
1483	High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma. 2015 , 10, e0142656	138
1482	The Mechanisms of Human Renal Epithelial Cell Modulation of Autologous Dendritic Cell Phenotype and Function. 2015 , 10, e0134688	8
1481	B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. 2015 , 10, e0135528	48
1480	PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. 2015 , 10, e0136023	167
1479	PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment. 2015 , 10, e0137646	43
1478	PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. 2015 , 10, e0139867	55
1477	PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. 2015 , 11, e1005270	31
1476	Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. 2015 , 4, 91-100	32
1475	Notch Signaling Pathway Was Involved in Regulating Programmed Cell Death 1 Expression during Sepsis-Induced Immunosuppression. 2015 , 2015, 539841	19
1474	Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma. 2015 , 2015, 341430	34

1473	Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage. 2015 , 2015, 856707	12
1472	Cancer and the Cellular Immune Response. 2015 , 695-708.e2	
1471	PD-L1 blockade for cancer treatment: MEDI4736. 2015 , 42, 474-83	71
1470	Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. 2015 , 212, 1125-37	242
1469	Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens. 2015 , 14, 487-98	165
1468	Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. 2015 , 15, 689-702	9
1467	A gender factor in shaping T-cell immunity to melanoma. 2015 , 5, 8	11
1466	Costimulation Immunotherapy in Infectious Diseases. 2015 , 83-129	3
1465	T-Cell Costimulation and Its Applications in Diseases. 2015 , 255-292	3
1464	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. 2015 , 94, 1545-52	56
1463	Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system. 2015 , 17, 30	8
1462	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. 2015 , 37, 764-82	360
1461	Human PD-1 binds differently to its human ligands: a comprehensive modeling study. 2015 , 57, 131-42	33
1460	Immunostimulators and Immunomodulators in Cancer Treatment. 2015 , 411-431	
1459	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. 2015 , 11, 133-40	9
1458	Immune checkpoint modulation for non-small cell lung cancer. 2015 , 21, 2256-62	72
1457	PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. 2015 , 3, 926-35	111
1456	Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1. 2015 , 194, 5520-8	45

1455	Programmed death-1 controls T cell survival by regulating oxidative metabolism. 2015 , 194, 5789-800	76
1454	PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma. 2015 , 89, 181-8	195
1453	Immunology. Expanding the role of metabolism in T cells. 2015 , 348, 976-7	17
1452	Beyond adjuvants: immunomodulation strategies to enhance T cell immunity. 2015 , 33 Suppl 2, B21-8	19
1451	Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model. 2015 , 64, 1095-108	15
1450	Kidney Cancer. 2015 ,	1
1449	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. 2014 , 4, 385	135
1448	The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy. 2014 , 5, 646	6
1447	Stimulating immune responses to fight cancer: Basic biology and mechanisms. 2015 , 11 Suppl 1, 9-15	8
1446	Checkpoint blockade in lymphoma. 2015 , 2015, 69-73	11
1445	Modification of sPD1 with CRT induces potent anti-tumor immune responses in vitro and in vivo. 2015 , 76, 57-64	1
1444	Developments in T Cell Based Cancer Immunotherapies. 2015 ,	
1443	Therapeutic Antibodies in Cancer Therapy. 2015 , 95-120	0
1442	Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review. 2015 , 14, 207	107
1441	Current status of checkpoint inhibitors in lymphoma. 2015 , 4, 167-174	
1440	Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways. 2015 , 17, 340	63
1439	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. 2015 , 7, 232-241	
1438	[Rationale, visions and limits of Immuno-oncology: Checkpoint inhibition as a new pillar of tumor therapy]. 2015 , 38 Suppl 3, 2-5	1

1437	The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis. 2015 , 42, 111-20	7
1436	Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. 2015 , 148, 590-602.e10	124
1435	Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. 2015 , 33, 90-6	28
1434	The programmed cell death 1 gene polymorphisms (PD 1.3 G/A, PD 1.5 C/T and PD 1.9 C/T) and susceptibility to ankylosing spondylitis: a meta-analysis. 2015 , 20, 55-63	17
1433	The 21st Century Handbook of Clinical Ovarian Cancer. 2015 ,	5
1432	Recent Insight into the Role of the PD-1/PD-L1 Pathway in Feto-Maternal Tolerance and Pregnancy. 2015 , 74, 201-8	44
1431	PD-1 suppresses protective immunity to Streptococcus pneumoniae through a B cell-intrinsic mechanism. 2015 , 194, 2289-99	25
1430	Overexpression of programmed death ligands in naturally occurring postweaning multisystemic wasting syndrome. 2015 , 28, 101-6	7
1429	Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. 2015 , 38, 1415-33	11
1428	Construction, expression, purification, and characterization of a dual-targeting PD-1/VEGF-A fusion protein (P-V). 2015 , 109, 1-6	2
1427	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. 2015 , 33, 23-35	246
1426	Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. 2015 , 26, 812-817	202
1425	Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. 2015 , 290, 8110-20	96
1424	Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants. 2015 , 15, 333-45	16
1423	Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. 2015 , 33, 1-8	22
1422	Hodgkin Lymphoma. 2015 ,	11
1421	Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets. 2015 , 21, 695-701	26
1420	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. 2015 , 112, E966-72	295

1419	CD4+ T cell hyporesponsiveness after repeated exposure to <i>Schistosoma mansoni</i> larvae is dependent upon interleukin-10. 2015 , 83, 1418-30	17
1418	Local-Regional Treatment of the Patient With Inflammatory Breast Cancer. 2015 , 7, 37-42	
1417	Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival. 2015 , 136, E95-106	21
1416	Human mesenchymal stromal cells enhance the immunomodulatory function of CD8(+)CD28(-) regulatory T cells. 2015 , 12, 708-18	53
1415	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. 2015 , 13, 5	55
1414	Targeted immune therapy of ovarian cancer. 2015 , 34, 53-74	23
1413	Nivolumab in NSCLC: latest evidence and clinical potential. 2015 , 7, 85-96	164
1412	Genetic variations of IL-28B and PD-1 are in association with the susceptibility and outcomes of HCV infection in Southeast China. 2015 , 32, 89-96	12
1411	Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. 2015 , 32, 86	75
1410	The immune response in cancer: from immunology to pathology to immunotherapy. 2015 , 467, 127-35	42
1409	Evolving Concepts: Immunity in Oncology from Targets to Treatments. 2015 , 2015, 847383	20
1408	Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis. 2014 , 5, 684	19
1407	Lung CD8+ T Cell Impairment Occurs during Human Metapneumovirus Infection despite Virus-Like Particle Induction of Functional CD8+ T Cells. 2015 , 89, 8713-26	17
1406	Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers. 2015 , 134, 208-14	15
1405	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. 2015 , 128, 263-307	85
1404	Combination cancer immunotherapy and new immunomodulatory targets. 2015 , 14, 561-84	806
1403	CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells. 2015 , 195, 1054-63	25
1402	High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy. 2015 , 117, 165-70	36

1401	Mucosal-associated invariant T cells are numerically and functionally deficient in patients with mycobacterial infection and reflect disease activity. 2015 , 95, 267-74	71
1400	Immune Checkpoint Inhibition in Renal Cell Carcinoma. 2015 , 259-279	
1399	The role of programmed death ligand 1 pathway in persistent biomaterial-associated infections. 2015 , 53, 544-52	6
1398	PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma. 2015 , 32, 212	67
1397	Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. 2015 , 166, 721-732.e1	70
1396	PDCD1 single nucleotide genes polymorphisms confer susceptibility to juvenile-onset systemic lupus erythematosus. 2015 , 48, 488-93	24
1395	Immunotherapy for multiple myeloma: Current status and future directions. 2015 , 96, 399-412	24
1394	Redundant and specialized roles for diacylglycerol kinases β and γ in the control of T cell functions. 2015 , 8, re6	46
1393	Treatment of Liver Cancer. 2015 , 5, a021535	144
1392	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. 2015 , 21, 4607-18	214
1391	Expression of Programmed Death 1 Ligand in Different Compartments of Chronic Lymphocytic Leukemia. 2015 , 134, 255-62	31
1390	Innate and Adaptive Cellular Immune Responses to Mycobacterium tuberculosis Infection. 2015 , 5,	50
1389	Feto-maternal immune regulation by TIM-3/galectin-9 pathway and PD-1 molecule in mice at day 14.5 of pregnancy. 2015 , 36, 1153-60	27
1388	Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication. 2015 , 75, 3279-91	39
1387	Programmed death-ligand 1, 2 expressions are decreased in the psoriatic epidermis. 2015 , 307, 531-8	16
1386	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. 2015 , 709-738.e8	
1385	Emerging immunological drugs for chronic lymphocytic leukemia. 2015 , 20, 423-47	9
1384	Vaccination of multiple myeloma: Current strategies and future prospects. 2015 , 96, 339-54	16

1383	Gammaherpesvirus Co-infection with Malaria Suppresses Anti-parasitic Humoral Immunity. 2015 , 11, e1004858	25
1382	Gaining momentum: New options and opportunities for the treatment of advanced melanoma. 2015 , 41, 660-70	46
1381	Reply to Stephen-Victor et al. 2015 , 211, 1029-31	
1380	Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy. 2015 , 107,	55
1379	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. 2015 , 5, 34	161
1378	Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. 2015 , 85, 703.e1-6	88
1377	Autologous hematopoietic SCT normalizes miR-16, -155 and -142-3p expression in multiple sclerosis patients. 2015 , 50, 380-9	66
1376	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. 2015 , 15, 509-23	18
1375	Update on metastatic gastric and esophageal cancers. 2015 , 33, 1760-9	138
1374	Immuno-regulatory antibodies for the treatment of cancer. 2015 , 15, 787-801	36
1373	Hepatic stellate cell-conditioned myeloid cells provide a novel therapy for prevention of factor VIII antibody formation in mice. 2015 , 43, 277-85	5
1372	Programmed cell death-1 inhibition in lymphoma. 2015 , 16, e234-45	40
1371	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. 2015 , 33, 2013-20	337
1370	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients. 2015 , 21, 3140-8	97
1369	Pembrolizumab for the treatment of non-small-cell lung cancer. 2015 , 372, 2018-28	3943
1368	Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine. 2015 , 10, 959-75	19
1367	The role of checkpoints in the treatment of GBM. 2015 , 123, 413-23	12
1366	Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. 2015 , 12, 14	102

1365	PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. 2015 , 88, 254-9	55
1364	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. 2015 , 75, 563-75	16
1363	Immune checkpoint blockade in hematologic malignancies. 2015 , 125, 3393-400	176
1362	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. 2015 , 240, 1087-98	37
1361	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. 2015 , 3, 399-411	289
1360	PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. 2015 , 194, 5801-11	109
1359	Tryptophan Metabolism: Implications for Biological Processes, Health and Disease. 2015 ,	3
1358	Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. 2015 , 42, 363-77	83
1357	IFN γ -producing CD8 T cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas. 2015 , 4, e974959	19
1356	Overcoming T cell exhaustion in infection and cancer. 2015 , 36, 265-76	619
1355	New insights into type I interferon and the immunopathogenesis of persistent viral infections. 2015 , 34, 91-8	32
1354	Advances in the treatment of prostate cancer with radiotherapy. 2015 , 95, 144-53	13
1353	Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions. 2015 , 194, 4413-21	22
1352	Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. 2015 , 16, e25-35	78
1351	Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. 2015 , 112, 6682-7	185
1350	Safety of pembrolizumab for the treatment of melanoma. 2015 , 14, 957-64	22
1349	Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody. 2015 , 3, 1052-62	226
1348	PD-1 deficiency enhances humoral immunity of malaria infection treatment vaccine. 2015 , 83, 2011-7	16

1347	PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors. 2015 , 38, 1-11	270
1346	Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. 2015 , 16, 17	43
1345	Immune checkpoint inhibition in lymphoid disease. 2015 , 170, 291-304	18
1344	Immunohistochemical markers in lymphoid malignancies: Protein correlates of molecular alterations. 2015 , 32, 381-91	3
1343	Up-regulation of Tim-3 on T cells during acute simian immunodeficiency virus infection and on antigen specific responders. 2015 , 29, 531-6	11
1342	Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma. 2015 , 38, 37-9	95
1341	A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. 2015 , 68, 267-79	144
1340	TGF- β -expressing CD4+CD25(-)LAG3+ regulatory T cells control humoral immune responses. 2015 , 6, 6329	78
1339	Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. 2015 , 21, 3178-86	23
1338	Immunologic correlates in the course of treatment with immunomodulating antibodies. 2015 , 42, 448-58	19
1337	The journey from discoveries in fundamental immunology to cancer immunotherapy. 2015 , 27, 439-49	157
1336	Immune checkpoint blockade: a common denominator approach to cancer therapy. 2015 , 27, 450-61	2410
1335	Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. 2015 , 161, 205-14	1388
1334	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. 2015 , 13, 265-72	146
1333	PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice. 2015 , 64, 529-40	16
1332	Targeting the immune system to treat lung cancer: rationale and clinical experience. 2015 , 9, 105-20	11
1331	NOD.H-2h4 mice: an important and underutilized animal model of autoimmune thyroiditis and Sjogren's syndrome. 2015 , 126, 1-43	30
1330	Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. 2015 , 27, 489-501	114

1329	Clinical significance of soluble programmed death-1(sPD-1) in rheumatoid arthritis patients: Relation to disease activity and functional status. 2015 , 37, 165-169	10
1328	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. 2015 , 28, 1535-44	58
1327	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. 2021 , 1-14	18
1326	Hepatic stellate cells: central modulators of hepatic carcinogenesis. 2015 , 15, 63	64
1325	Several immune escape patterns in non-Hodgkin's lymphomas. 2015 , 4, e1026530	62
1324	Effects of DKK-3, a Wnt signaling inhibitor, on dendritic cell phenotype and T cell polarization. 2015 , 37, 481-7	5
1323	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. 2015 , 7, 777-92	16
1322	Heteroclitic Peptides Increase Proliferation and Reduce Evidence of Human Immunodeficiency Virus-Specific CD8+ T Cell Dysfunction. 2015 , 28, 455-63	5
1321	Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters. 2015 , 28, 418-24	16
1320	Frequent PD-L1 expression in testicular germ cell tumors. 2015 , 113, 411-3	100
1319	Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy. 2015 , 16, 39	73
1318	Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. 2015 , 6, 534-8	86
1317	Emerging Therapeutic Targets for Male Germ Cell Tumors. 2015 , 17, 54	7
1316	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. 2015 , 16, 54	35
1315	Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. 2015 , 5, e285	68
1314	Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. 2015 , 1, 66-75	60
1313	Chemical compounds from anthropogenic environment and immune evasion mechanisms: potential interactions. 2015 , 36 Suppl 1, S111-27	34
1312	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. 2015 , 14, 119	35

1311	Association of genetic polymorphisms in CD8+ T cell inhibitory genes and susceptibility to and progression of chronic HBV infection. 2015 , 36, 467-474	9
1310	Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming. 2015 , 11, 2705-15	3
1309	Current position of TNF- α in melanomagenesis. 2015 , 36, 6589-602	9
1308	Lung cancer: Biology and treatment options. 2015 , 1856, 189-210	322
1307	Salmonella induces PD-L1 expression in B cells. 2015 , 167, 131-40	10
1306	Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. 2015 , 4, e1016700	156
1305	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. 2015 , 162, 1229-41	1457
1304	Nutrient Competition: A New Axis of Tumor Immunosuppression. 2015 , 162, 1206-8	69
1303	Impaired T-bet-pSTAT1 α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma. 2015 , 113, 902-13	12
1302	Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. 2015 , 33, 4015-22	691
1301	Multiplying therapies and reducing toxicity in metastatic melanoma. 2015 , 16, 1014-8	9
1300	Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes. 2015 , 191, 75-83	4
1299	B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. 2015 , 195, 3584-95	9
1298	PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity. 2015 , 7, 1145-58	8
1297	Programmed cell death-1 is expressed in large retinal ganglion cells and is upregulated after optic nerve crush. 2015 , 140, 1-9	9
1296	Salmonella impairs CD8 T cell response through PD-1: PD-L axis. 2015 , 220, 1369-80	10
1295	Nivolumab for treating non-small cell lung cancer. 2015 , 15, 1789-97	19
1294	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. 2015 , 7, 365-77	90

1293	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. 2015 , 9, 1936-65	55
1292	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- κ B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. 2015 , 75, 5034-45	318
1291	Tremelimumab for the treatment of malignant mesothelioma. 2015 , 15, 1819-29	17
1290	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. 2015 , 19, 201-11	66
1289	T cell exhaustion and Interleukin 2 downregulation. 2015 , 71, 339-47	36
1288	The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. 2015 , 62, 190-197	23
1287	Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. 2015 , 147, 63-79	23
1286	Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. 2015 , 21, 451-67	74
1285	Novel immunotherapies for hematologic malignancies. 2015 , 263, 90-105	37
1284	Clinical blockade of PD1 and LAG3--potential mechanisms of action. 2015 , 15, 45-56	398
1283	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. 2015 , 372, 311-9	2513
1282	B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease. 2015 , 194, 560-74	45
1281	Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation. 2015 , 172, 940-50	39
1280	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. 2015 , 21, 24-33	415
1279	Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells. 2015 , 21, 471-83	46
1278	Difference in skin immune responses to infection with salmon louse (<i>Lepeophtheirus salmonis</i>) in Atlantic salmon (<i>Salmo salar</i> L.) of families selected for resistance and susceptibility. 2015 , 42, 384-94	45
1277	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. 2015 , 27, 39-46	222
1276	Protective effects of Fc-fused PD-L1 on two different animal models of colitis. 2015 , 64, 260-71	59

1275	Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. 2015 , 29, 25-32	32
1274	[Application of immunomodulatory therapeutic antibodies - a new perspective in oncology]. 2016 , 157 Suppl 2, 9-16	1
1273	Immuntherapien beim Mammakarzinom [Wie hängen Immunsystem und Krebs zusammen und woran arbeitet die Forschung?]. 2016 , 13, 169-172	
1272	Current advances in biomarkers for targeted therapy in triple-negative breast cancer. 2016 , 8, 183-197	25
1271	PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. 2016 , 7, 24269-83	178
1270	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. 2016 , 9, 5855-5866	8
1269	Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials. 2016 , 10, 85-91	24
1268	Nonmuscle invasive bladder cancer: a primer on immunotherapy. 2016 , 13, 194-205	14
1267	Association of the programmed cell death-1 PD1.5 C>T polymorphism with cervical cancer risk in a Chinese population. 2016 , 15,	10
1266	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability . PD-L1. 2016 , 7, 771-788	61
1265	Basic Overview of Current Immunotherapy Approaches in Cancer. 2016 , 35, 298-308	63
1264	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. 2016 , 35, 34-42	55
1263	Immune checkpoint therapy for pancreatic cancer. 2016 , 22, 9457-9476	60
1262	Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants. 2016 , 7, 32318-28	105
1261	Treatment of brain metastases of lung cancer in the era of precision medicine. 2016 , 8, 219-32	7
1260	Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer Cells. 2016 , 2016, 1490738	24
1259	PD-1/PD-L1 Interaction Maintains Allogeneic Immune Tolerance Induced by Administration of Ultraviolet B-Irradiated Immature Dendritic Cells. 2016 , 2016, 2419621	
1258	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. 2016 , 2016, 4683607	29

1257	Common Variable Immunodeficiency and Circulating TFH. 2016 , 2016, 4951587	21
1256	Development of Novel Immunotherapies for Multiple Myeloma. 2016 , 17,	18
1255	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. 2016 , 7, 34341-55	185
1254	Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer. 2016 , 19, 242-251	45
1253	High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers. 2016 , 6, 1629-40	138
1252	Clinical utility of nivolumab in the treatment of advanced melanoma. 2016 , 12, 313-25	12
1251	Harnessing the immune system to improve cancer therapy. 2016 , 4, 261	167
1250	PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients. 2016 , 7, 126	17
1249	The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis. 2016 , 7, 153	33
1248	Features of Memory-Like and PD-1(+) Human NK Cell Subsets. 2016 , 7, 351	83
1247	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. 2016 , 7, 550	282
1246	Therapeutic Immune Tolerance Approaches for the Treatment of Allergic Disease. 2016 , 259-284	
1245	A Perspective of Immunotherapy for Prostate Cancer. 2016 , 8,	21
1244	Advances in Cancer Immunotherapy in Solid Tumors. 2016 , 8,	109
1243	Biology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma. 2016 , 8,	30
1242	PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays. 2016 , 17,	16
1241	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. 2016 , 17,	93
1240	Development of a Modular Assay for Detailed Immunophenotyping of Peripheral Human Whole Blood Samples by Multicolor Flow Cytometry. 2016 , 17,	49

1239	Immunoregulation in Fungal Diseases. 2016 , 4,	10
1238	Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. 2016 , 11, e0152448	28
1237	CD4 T Cell-Derived IFN- γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease. 2016 , 12, e1005667	198
1236	PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis. 2016 , 11, e0160485	25
1235	Activation, Impaired Tumor Necrosis Factor- β Production, and Deficiency of Circulating Mucosal-Associated Invariant T Cells in Patients with Scrub Typhus. 2016 , 10, e0004832	18
1234	Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy. 2016 , 11, e0146622	17
1233	Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma. 2016 , 11, e0150030	20
1232	A Cinnamon-Derived Procyanidin Compound Displays Anti-HIV-1 Activity by Blocking Heparan Sulfate- and Co-Receptor- Binding Sites on gp120 and Reverses T Cell Exhaustion via Impeding Tim-3 and PD-1 Upregulation. 2016 , 11, e0165386	20
1231	TLR3-Induced Maturation of Murine Dendritic Cells Regulates CTL Responses by Modulating PD-L1 Trafficking. 2016 , 11, e0167057	14
1230	PD-L1 expression in human cancers and its association with clinical outcomes. 2016 , 9, 5023-39	370
1229	Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. 2016 , 9, 5101-16	26
1228	Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. 2016 , 9, 4805-13	29
1227	PD-1/PD-L1 blockades in non-small-cell lung cancer therapy. 2016 , 9, 489-502	40
1226	Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. 2016 , 7, 17194-211	62
1225	Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. 2016 , 22, 17-22	13
1224	Immune Checkpoint Therapy in Head and Neck Cancers. 2016 , 22, 108-16	10
1223	Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. 2016 , 22, 130-7	29
1222	Effect of PD-1: PD-L1 in Invariant Natural Killer T-Cell Emigration and Chemotaxis Following Sepsis. 2016 , 45, 534-9	9

1221	Menopausal status influences the expression of programmed death (PD)-1 and its ligand PD-L1 on immune cells from the human female reproductive tract. 2016 , 76, 118-25	14
1220	Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines. 2016 , 39, 171-80	65
1219	Pembrolizumab (Keytruda). 2016 , 12, 2777-2789	127
1218	Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. 2016 , 40, 443-53	35
1217	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. 2016 , 8, 319-326	20
1216	An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors. 2016 , 107, 108-19	44
1215	What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma. 2016 , 16, 483-487	1
1214	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. 2016 , 48, 61-8	77
1213	Inhibitors of programmed cell death 1 (PD-1): a patent review (2010-2015). 2016 , 26, 973-7	67
1212	Intratumoral expression levels of , , and along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. 2016 , 5, e1204507	87
1211	Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives. 2016 , 138, 2549-61	119
1210	Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. 2016 , 54, 157-61	73
1209	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. 2016 , 101, 794-802	62
1208	Novel Targets and Their Assessment for Cancer Treatment. 2016 , 163-180	
1207	The current status of checkpoint inhibitors in metastatic bladder cancer. 2016 , 33, 629-35	9
1206	Immunotherapy for genitourinary cancer: state of the art and new perspectives. 2016 , 27, 585-99	4
1205	Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies. 2016 , 55, 428-41	29
1204	EBV-Positive and EBV-Negative Posttransplant Diffuse Large B Cell Lymphomas Have Distinct Genomic and Transcriptomic Features. 2016 , 16, 414-25	51

1203	Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas. 2016 , 68, 1079-89	102
1202	Immunotherapy for breast cancer: past, present, and future. 2016 , 35, 525-546	27
1201	Early detection and personalized treatment in oral cancer: the impact of omics approaches. 2016 , 9, 85	24
1200	Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. 2016 , 6, 20090	111
1199	Mechanisms and Strategies for Tolerance in Liver Transplantation. 2016 , 3, 325-333	
1198	Biochemistry of Oxidative Stress. 2016 ,	3
1197	Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. 2016 , 1, e000083	45
1196	PD-L1 is upregulated by EBV-driven LMP1 through NF- κ B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma. 2016 , 9, 109	150
1195	A20 Curtails Primary but Augments Secondary CD8 T Cell Responses in Intracellular Bacterial Infection. 2016 , 6, 39796	14
1194	Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. 2016 , 8, 116	12
1193	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. 2016 , 6, 25952	29
1192	Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer. 2016 , 24, 392-7	197
1191	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. 2016 , 4, 81	37
1190	Immune-related endocrine disorders in novel Immune checkpoint inhibition therapy. 2016 , 3, 252-256	15
1189	Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease. 2016 , 6, 26747	19
1188	Immuntherapien beim Mammakarzinom [Wie hängen Immunsystem und Krebs zusammen und woran arbeitet die Forschung?]. 2016 , 76, 503-506	
1187	Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. 2016 , 54, 17-24	100
1186	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. 2016 , 5, e1165377	38

1185	Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. 2016,	2
1184	High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. 2016, 59, 152-159	137
1183	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. 2016, 9, 47	221
1182	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. 2016, 17, 956-965	1007
1181	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. 2016, 48, 428-439	26
1180	Therapeutic Antibodies in Cancer Therapy. 2016, 917, 95-120	26
1179	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. 2016, 76, 925-45	100
1178	Inhibitory immunologiczných punktů kontrolných podziaů komůki w leczeniu chorů nowotworowych. 2016, 47, 155-162	1
1177	PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. 2016, 44, 1190-203	66
1176	Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. 2016, 44, 1052-68	152
1175	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. 2016, 22, 5487-5496	373
1174	Severe pneumonitis after nivolumab treatment in a patient with melanoma. 2016, 65, 487-489	19
1173	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. 2016, 8, 733-46	19
1172	Phase I study to evaluate toxicity and feasibility of intratumoral injection of ßgal glycolipids in patients with advanced melanoma. 2016, 65, 897-907	8
1171	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. 2016, 37, 462-476	171
1170	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). 2016, 96, 1-6	26
1169	Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. 2016, 8, 203-14	8
1168	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. 2016, 16, 989-1004	9

1167	TALEN-Mediated Inactivation of PD-1 in Tumor-Reactive Lymphocytes Promotes Intratumoral T-cell Persistence and Rejection of Established Tumors. 2016 , 76, 2087-93	55
1166	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. 2016 , 34, 2690-7	472
1165	The significance and therapeutic potential of PD-1 and its ligands in ovarian cancer: A systematic review. 2016 , 142, 184-189	14
1164	Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma. 2016 , 37, 7507-14	32
1163	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines. 2016 , 95, e3134	12
1162	Immune checkpoint inhibition in ovarian cancer. 2016 , 28, 339-48	96
1161	Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. 2016 , 140, 341-4	98
1160	Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. 2016 , 44, 924-38	544
1159	Cancer immunotherapy: the beginning of the end of cancer?. 2016 , 14, 73	651
1158	Chordoma: The Quest for Better Treatment Options. 2016 , 4, 35-51	23
1157	Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. 2016 , 18, 43	67
1156	Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?. 2016 , 12, 101-6	9
1155	Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. 2016 , 34, 2460-7	867
1154	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. 2016 , 17, 717-726	716
1153	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. 2016 , 13, 473-86	591
1152	Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission. 2016 , 44, 1204-14	95
1151	Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphoma. 2016 , 51, 1268-70	57
1150	Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?. 2016 , 33, 59	20

1149	Tim-3 identifies exhausted follicular helper T cells in breast cancer patients. 2016 , 221, 986-93	32
1148	Targetable genetic features of primary testicular and primary central nervous system lymphomas. 2016 , 127, 869-81	317
1147	Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. 2016 , 127, 3350-9	27
1146	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. 2016 , 127, 3026-34	126
1145	Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. 2016 , 24, 1719-1728	53
1144	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. 2016 , 12, 2683-2688	12
1143	Cooperation of PD-1 and LAG-3 Contributes to T-Cell Exhaustion in Anaplasma marginale-Infected Cattle. 2016 , 84, 2779-90	26
1142	Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis. 2016 , 469, 581-590	53
1141	Review on the immunotherapy strategies against metastatic colorectal carcinoma. 2016 , 8, 1245-61	6
1140	Progress and opportunities for immune therapeutics in osteosarcoma. 2016 , 8, 1233-44	28
1139	Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential. 2016 , 8, 1219-32	17
1138	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. 2016 , 3, 195-202	10
1137	Decreased expression of programmed death 1 on peripheral blood lymphocytes disrupts immune homeostasis in peripartum cardiomyopathy. 2016 , 223, 842-847	6
1136	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. 2016 , 34, 3838-3845	525
1135	CD4Foxp3 type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and are regulated by tumor-associated macrophages. 2016 , 81, 1-9	20
1134	Antigen-Specific Immune Modulation Targets mTORC1 Function To Drive Chemokine Receptor-Mediated T Cell Tolerance. 2016 , 197, 3554-3565	2
1133	T follicular helper cells in patients with acute schistosomiasis. 2016 , 9, 321	10
1132	TGFβ-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer. 2016 , 6, 1366-1381	131

1131	Trends and advances in tumor immunology and lung cancer immunotherapy. 2016 , 35, 157	34
1130	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. 2016 , 101, 1144-1158	6
1129	Coming-of-Age of Antibodies in Cancer Therapeutics. 2016 , 37, 1009-1028	69
1128	Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. 2016 , 14, 685-97	2
1127	Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. 2016 , 11, 95	128
1126	CD4FOXP3 T regulatory cells decrease and CD3CD8 T cells recruitment in TILs from melanoma metastases after electrochemotherapy. 2016 , 33, 787-798	18
1125	Metastatic melanoma and immunotherapy. 2016 , 172, 105-110	31
1124	The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer. 2016 , 16, 903-10	5
1123	Cord Blood Hematopoietic Cell Transplantation. 2016 , 437-455	5
1122	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. 2016 , 61, 152-8	40
1121	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. 2016 , 12, 2997-3004	9
1120	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. 2016 , 34, 677-684	22
1119	Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma. 2016 , 12, 1247-53	32
1118	The untold story of IFN- γ in cancer biology. 2016 , 31, 73-81	65
1117	Deciphering new mechanisms on T-cell costimulation by human mast cells. 2016 , 46, 1105-8	1
1116	Characterization of age-associated exhausted CD8+ T cells defined by increased expression of Tim-3 and PD-1. 2016 , 15, 291-300	50
1115	Pembrolizumab in classical Hodgkin's lymphoma. 2016 , 97, 219-27	16
1114	Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. 2016 , 27, 1966-9	19

1113	T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases. 2016 , 94, 935-942	21
1112	Rel B-modified dendritic cells possess tolerogenic phenotype and functions on lupus splenic lymphocytes in vitro. 2016 , 149, 48-61	10
1111	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. 2016 , 15, 55	151
1110	Management of Lung Cancer in the Elderly. 2016 , 170, 251-84	8
1109	Complementary Effects of Interleukin-15 and Alpha Interferon Induce Immunity in Hepatitis B Virus Transgenic Mice. 2016 , 90, 8563-74	14
1108	Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. 2016 , 140, 1243-1249	74
1107	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. 2016 , 89, 20160472	28
1106	Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma. 2016 , 209, 365-375	20
1105	Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity. 2016 , 45, 333-45	73
1104	Immunotherapy in Lung Cancer. 2016 , 170, 203-23	6
1103	HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. 2016 , 6, 31154	46
1102	Understanding immunotherapy for the treatment of non-small cell lung cancer. 2016 , 25, S12-7	1
1101	PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher. 2016 , 9, 939-49	9
1100	PD-1/PD-L and autoimmunity: A growing relationship. 2016 , 310, 27-41	149
1099	Checkpoint inhibitors in lung cancer: latest developments and clinical potential. 2016 , 8, 460-473	26
1098	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. 2016 , 127, 2489-97	71
1097	Hepatitis B core antigen upregulates B7-H1 on dendritic cells by activating the AKT/ERK/P38 pathway: a possible mechanism of hepatitis B virus persistence. 2016 , 96, 1156-1164	7
1096	Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. 2016 , 152, 1128-1136	129

1095	PD-L1 expression is associated with advanced non-small cell lung cancer. 2016 , 12, 921-927	17
1094	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. 2016 , 12, 944-950	47
1093	Engagement of distinct epitopes on CD43 induces different co-stimulatory pathways in human T cells. 2016 , 149, 280-296	5
1092	B cell regulation of the anti-tumor response and role in carcinogenesis. 2016 , 4, 40	141
1091	Immune checkpoint inhibitors: a milestone in the treatment of melanoma. 2016 , 14, 685-95	13
1090	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction. 2016 , 5, e1202390	25
1089	Biology and Management of Patients With Triple-Negative Breast Cancer. 2016 , 21, 1050-62	131
1088	Co-stimulate or Co-inhibit Regulatory T Cells, Which Side to Go?. 2016 , 45, 813-831	15
1087	Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. 2016 , 63, e1-e3	6
1086	miR-24, miR-30b and miR-142-3p interfere with antigen processing and presentation by primary macrophages and dendritic cells. 2016 , 6, 32925	47
1085	IL-27 Is Essential for Suppression of Experimental Allergic Asthma by the TLR7/8 Agonist R848 (Resiquimod). 2016 , 197, 4219-4227	25
1084	PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. 2016 , 5, e1254856	34
1083	BTLA identifies dysfunctional PD-1-expressing CD4 T cells in human hepatocellular carcinoma. 2016 , 5, e1254855	26
1082	Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS). 2016 , 14, 312	18
1081	Nivolumab in melanoma. 2016 , 16, 1247-1261	16
1080	Genetic Dissection of Autoinflammatory Syndrome. 2016 , 63-75	
1079	Characterization of T follicular helper cells in allogeneic normal pregnancy and PDL1 blockage-induced abortion. 2016 , 6, 36560	19
1078	CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients. 2016 , 6, 20070	188

1077	Immune checkpoint inhibitors for cancer treatment. 2016 , 39, 1577-1587	29
1076	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. 2016 , 6, 30093	155
1075	Novel CD200 homologues iSEC1 and iSEC2 are gastrointestinal secretory cell-specific ligands of inhibitory receptor CD200R. 2016 , 6, 36457	8
1074	High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy. 2016 , 9, 132	31
1073	Current Status of Immunotherapy Treatments for Pancreatic Cancer. 2016 , 50, 836-848	10
1072	Host-directed therapies for antimicrobial resistant respiratory tract infections. 2016 , 22, 203-11	13
1071	Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report. 2016 , 95, e5077	1
1070	Programed death-1/programed death-ligand 1 expression in lymph nodes of HIV infected patients: results of a pilot safety study in rhesus macaques using anti-programed death-ligand 1 (Avelumab). 2016 , 30, 2487-2493	20
1069	Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types. 2016 , 5, 5	34
1068	Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. 2016 , 85, 331-9	137
1067	The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. 2016 , 38, 81-9	26
1066	Harnessing the antitumor immunity cycle to treat lung cancer. 2016 , 5, 40-48	
1065	Investigational targeted therapies for the treatment of testicular germ cell tumors. 2016 , 25, 1033-43	19
1064	Radiobiology of Glioblastoma. 2016 ,	2
1063	Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. 2016 , 5, e1181252	41
1062	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. 2016 , 34, 3119-25	601
1061	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. 2016 , 21, 804-16	156
1060	From Molecular to Clinical Radiation Biology of Glioblastoma. 2016 , 275-292	

1059	Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). 2016 , 33, 80	27
1058	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. 2016 , 13, 420-31	66
1057	Unintended Immunological Consequences of Biologic Therapy. 2016 , 16, 46	12
1056	Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation. 2016 , 169, 47-57	37
1055	[Immunological aspects of ovarian cancer: Therapeutic perspectives]. 2016 , 45, 1020-1036	1
1054	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. 2016 , 43, 501-13	8
1053	CD8(+) T cells in human autoimmune arthritis: the unusual suspects. 2016 , 12, 421-8	47
1052	Program Death-1 Suppresses Autoimmune Arthritis by Inhibiting Th17 Response. 2016 , 64, 417-23	9
1051	The PD-1:PD-L1 immune inhibitory checkpoint in <i>Helicobacter pylori</i> infection and gastric cancer: a comprehensive review and future perspectives. 2016 , 1, 4-11	8
1050	Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. 2016 , 21, 946-952	33
1049	Current and future immunotherapeutic approaches in Hodgkin lymphoma. 2016 , 57, 2014-24	16
1048	PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. 2016 , 6, 477-8	26
1047	Novel Immunotherapeutic Approaches to the Treatment of Cancer. 2016 ,	1
1046	Personalized immunotherapy in colorectal cancer. 2016 , 1, 267-277	2
1045	Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers. 2016 , 18, 50	42
1044	PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus. 2016 , 18, 47	37
1043	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. 2016 , 1-39	
1042	Der Warburg-Effekt im Duell von Tumorzellen und Immunsystem. 2016 , 50, 305-309	1

1041	Immune Checkpoint inhibitors: An introduction to the next-generation cancer immunotherapy. 2016 , 56, 157-69	75
1040	Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. 2016 , 34, 3733-3739	486
1039	Adaptive Immunity. 2016 , 206-224.e3	0
1038	Mechanisms of immunological tolerance. 2016 , 49, 324-8	13
1037	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. 2016 , 4, 3	146
1036	Testicular immunoregulation and spermatogenesis. 2016 , 59, 157-165	41
1035	Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC. 2016 , 35, 4345-57	24
1034	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. 2016 , 76, 1381-90	307
1033	A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity. 2016 , 31, 248-56	11
1032	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. 2016 , 6, 446-59	147
1031	Perspective on a Modified Developmental and Reproductive Toxicity Testing Strategy for Cancer Immunotherapy. 2016 , 35, 263-73	5
1030	Pembrolizumab for the treatment of non-small cell lung cancer. 2016 , 16, 397-406	52
1029	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. 2016 , 43, 113-23	8
1028	Recombinant factor VIII Fc (rFVIII Fc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice. 2016 , 301, 30-9	44
1027	Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. 2016 , 1863, 471-482	67
1026	Role of interferon- γ and cytotoxic T lymphocytes in intraocular tumor rejection. 2016 , 99, 735-47	6
1025	Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. 2016 , 2, 46-54	527
1024	IL-10/IFN γ -expressing CD4(+) T cells induced by IL-10 DC display a regulatory gene profile and downmodulate T cell responses. 2016 , 162, 91-9	7

1023	CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. 2016 , 39, 98-106	1102
1022	Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. 2016 , 4, 481-7	39
1021	TGF β Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis. 2016 , 76, 2525-39	110
1020	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. 2016 , 28, 383-91	146
1019	Immunotherapy for head and neck cancer: latest developments and clinical potential. 2016 , 8, 168-75	12
1018	Checkpoint inhibitors in Hodgkin's lymphoma. 2016 , 96, 335-43	11
1017	Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets. 2016 , 31, 1393-404	19
1016	Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. 2016 , 178, 31-6	11
1015	Infection with equine infectious anemia virus vaccine strain EIAVDLV121 causes no visible histopathological lesions in target organs in association with restricted viral replication and unique cytokine response. 2016 , 170, 30-40	2
1014	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. 2016 , 5, e1091146	38
1013	CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. 2016 , 22, 3571-81	132
1012	Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer. 2016 , 20, 175-81	26
1011	Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. 2016 , 7, 10501	846
1010	Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. 2016 , 52, 9-18	68
1009	Checkpoint Inhibitors for the Treatment of Hodgkin Lymphoma. 2016 , 12, 673-9	4
1008	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. 2016 , 29, 285-296	227
1007	Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. 2016 , 9, 32-40	13
1006	Human Immunodeficiency Virus Infection and Host Defense in the Lungs. 2016 , 37, 147-56	9

1005	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. 2016 , 21, 462-73	190
1004	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016 , 34, 539-73	34.7 507
1003	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. 2016 , 46, 1341-7	26
1002	KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. 2016 , 97, 163-71	17
1001	Immunotherapy of Cancer. 2016 ,	2
1000	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. 2016 , 11, 524-36	32
999	Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. 2016 , 7, e2115	46
998	Peptide Vaccine. 2016 , 135-142	
997	Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. 2016 , 8, 593-603	109
996	Immune checkpoint pathways: perspectives on myeloid malignancies. 2016 , 57, 995-1001	3
995	Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. 2016 , 34, 171-81	31
994	Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. 2016 , 17, 593-603	52
993	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. 2016 , 5, e1064578	65
992	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. 2016 , 34, 1510-7	509
991	"Endocytic pH regulates cell surface localization of glycolipid antigen loaded CD1d complexes". 2016 , 194, 49-57	4
990	Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. 2016 , 64, 1274-82	43
989	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. 2016 , 15, 235-47	358
988	Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. 2016 , 29, 528-41	42

987	Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. 2016 , 9, 419-28	21
986	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. 2016 , 27, 409-16	429
985	Mannose-Capped Lipoarabinomannan from Mycobacterium tuberculosis Induces CD4+ T Cell Anergy via GRAIL. 2016 , 196, 691-702	27
984	Allogeneic cardiosphere-derived cells for myocardial regeneration: current progress and recent results. 2016 , 12, 87-100	15
983	Whom to blame for metastasis, the epithelial-mesenchymal transition or the tumor microenvironment?. 2016 , 380, 359-68	40
982	Emerging drugs for the treatment of sepsis. 2016 , 21, 27-37	16
981	Immune checkpoint blockade: Releasing the brake towards hematological malignancies. 2016 , 30, 189-200	26
980	New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. 2016 , 9, 377-88	14
979	Reprogramming away from the exhausted T cell state. 2016 , 28, 35-44	18
978	PD-1 expression conditions T cell avidity within an antigen-specific repertoire. 2016 , 5, e1104448	38
977	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. 2016 , 22, 1969-77	128
976	Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. 2016 , 16, 5-12	12
975	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF- κ B. 2016 , 76, 239-50	62
974	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. 2016 , 9, 123-35	2
973	The role of microenvironment and immunity in drug response in leukemia. 2016 , 1863, 414-426	51
972	PD-1 expression on dendritic cells suppresses CD8 T cell function and antitumor immunity. 2016 , 5, e1085146	90
971	Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. 2016 , 6, 71-9	257
970	Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. 2016 , 1865, 58-71	43

969	Immunotherapy and tumor microenvironment. 2016 , 370, 85-90	164
968	Programmed Death Ligand 1 Promotes Early-Life Chlamydia Respiratory Infection-Induced Severe Allergic Airway Disease. 2016 , 54, 493-503	17
967	Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. 2016 , 97, 65-71	25
966	Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. 2016 , 24, 166-74	133
965	Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins. 2016 , 57, 537-56	16
964	From T cell "exhaustion" to anti-cancer immunity. 2016 , 1865, 49-57	13
963	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. 2016 , 30, 484-91	154
962	Activated human B cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return. 2016 , 75, 924-32	15
961	Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer. 2017 , 17, 528-534	7
960	Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. 2017 , 139, 335-346.e3	269
959	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. 2017 , 14, 115-128	62
958	Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. 2017 , 6, e1163456	22
957	PD-L1, Galectin-9 and CD8 tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. 2017 , 6, e1273309	93
956	Strategies to overcome therapeutic resistance in renal cell carcinoma. 2017 , 35, 102-110	26
955	Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions. 2017 , 222, 137-147	13
954	Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. 2017 , 96, 919-927	16
953	Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. 2017 , 15, e521-e524	12
952	Genomic insights in gynecologic cancer. 2017 , 41, 8-36	7

951	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. 2017 , 18, 212-220	246
950	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. 2017 , 29, 207-217	5
949	Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. 2017 , 25, 232-248	88
948	Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. 2017 , 284, 1952-1966	82
947	Host controls of HIV broadly neutralizing antibody development. 2017 , 275, 79-88	53
946	Novel immune check point inhibiting antibodies in cancer therapy-Opportunities and challenges. 2017 , 30, 39-47	56
945	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. 2017 , 5, 106-117	162
944	Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. 2017 , 69, 687-699	78
943	Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. 2017 , 331, 1-53	30
942	U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab. 2017 , 23, 3484-3488	79
941	Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors. 2017 , 15, 1527-1536	15
940	Safety issues and management of toxicities associated with new treatments for multiple myeloma. 2017 , 10, 193-205	5
939	Programmed cell death-1 expression correlates with disease severity and IL-5 in chronic rhinosinusitis with nasal polyps. 2017 , 72, 985-993	15
938	[The "immune checkpoints", how does it work]. 2017 , 37, 18-28	2
937	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. 2017 , 11, 358-372	31
936	State of the art in anti-cancer mAbs. 2017 , 24, 15	53
935	Immunotherapy comes of age: Immune aging & checkpoint inhibitors. 2017 , 8, 229-235	71
934	Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge. 2017 , 38, 513-525	25

933	NLRCS/CITA: A Key Player in Cancer Immune Surveillance. 2017 , 3, 28-38	36
932	PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. 2017 , 7, 44173	50
931	and kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. 2017 , 292, 6799-6809	10
930	Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. 2017 , 355, 1423-1427	486
929	T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. 2017 , 355, 1428-1433	764
928	Human bronchial epithelium orchestrates dendritic cell activation in severe asthma. 2017 , 49,	21
927	Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. 2017 , 30, 826-833	71
926	The Balance between CD8 T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. 2017 , 25, 880-891	32
925	The role of follicular T helper cells in patients with malignant lymphoid disease. 2017 , 22, 412-418	7
924	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. 2017 , 17, 30-44	42
923	Epitope mapping reveals the binding mechanism of a functional antibody cross-reactive to both human and murine programmed death 1. 2017 , 9, 628-637	7
922	New monoclonal antibodies on the horizon in multiple myeloma. 2017 , 8, 41-53	13
921	Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. 2017 , 188, 455-466	38
920	Targeting the programmed death-1 pathway in lymphoid neoplasms. 2017 , 54, 99-109	18
919	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. 2017 , 129, 2186-2197	109
918	Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm. 2017 , 56, 221-228	76
917	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. 2017 , 14, 1049-1065	15
916	Clinical effect and immunological response in patients with advanced malignant glioma treated with WT1-pulsed dendritic cell-based immunotherapy: A report of two cases. 2017 , 9, 24-29	4

915	Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma. 2017 , 6, e1269047	35
914	Regulation of microglial activation in stroke. 2017 , 38, 445-458	169
913	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. 2017 , 17, 515-523	36
912	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. 2017 , 44, 41-54	35
911	Cancer Immunotherapy. 2017 , 1-23	
910	Anti-Programmed Death 1 (PD1). 2017 , 57-66	1
909	Childhood Acute Lymphoblastic Leukemia. 2017 ,	
908	Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy. 2017 , 18, 597-611	11
907	Nivolumab induced myxedema crisis. 2017 , 5, 13	34
906	Primary Cutaneous Follicular Helper T-Cell Lymphoma: A Case Series and Review of the Literature. 2017 , 39, 374-383	7
905	WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. 2017 ,	
904	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. 2017 , 28, 1388-1398	54
903	Expression and prognostic significance of programmed death protein 1 and programmed death ligand-1, and cytotoxic T lymphocyte-associated molecule-4 in hepatocellular carcinoma. 2017 , 125, 690-698	41
902	Elevated T cell activation score is associated with improved survival of breast cancer. 2017 , 164, 689-696	25
901	Reconstitution of immune cell populations in multiple sclerosis patients after autologous stem cell transplantation. 2017 , 189, 268-278	42
900	Molecular Markers for Colorectal Cancer. 2017 , 97, 683-701	18
899	Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis. 2017 , 96, e6369	113
898	TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. 2017 , 39, 1010428317698352	11

897	Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?. 2017 , 12, 227-233	4
896	PD-1 regulates KLRG1 group 2 innate lymphoid cells. 2017 , 214, 1663-1678	124
895	Checkpoint inhibitors in hematological malignancies. 2017 , 10, 103	79
894	Programmed cell death ligand 1 as a biomarker in head and neck cancer. 2017 , 125, 529-533	1
893	Trends in Scientific Discovery. 2017 , 31-64	
892	Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. 2017 , 141, 572-582	41
891	Is autoimmunity the Achilles' heel of cancer immunotherapy?. 2017 , 23, 540-547	257
890	Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy. 2017 , 114, 33-42	60
889	Management of Lymphomas: A Case-Based Approach. 2017 ,	
888	Progress and challenges in the treatment of small cell lung cancer. 2017 , 34, 110	22
887	Resistance to PD1/PDL1 checkpoint inhibition. 2017 , 52, 71-81	305
886	Novel therapeutic strategies in the treatment of triple-negative breast cancer. 2017 , 9, 493-511	44
885	Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung. 2017 , 6, 131-134	2
884	Update on Radiotherapy for Central Nervous System Malignancies. 2017 , 26, 347-355	3
883	Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study. 2017 , 43, 1915-1923	17
882	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. 2017 , 8, 861-877	43
881	PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. 2017 , 545, 495-499	912
880	Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets. 2017 , 41, 998-1004	28

879	sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis. 2017 , 86, 100-106	21
878	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. 2017 , 5, 480-492	196
877	Immunogenomics: using genomics to personalize cancer immunotherapy. 2017 , 471, 209-219	5
876	Lymphocyte Activation Gene 3 (LAG-3). 2017 , 375-383	1
875	Immune Checkpoint Blockade and Gastric Cancer. 2017 , 115-130	2
874	Delivering safer immunotherapies for cancer. 2017 , 114, 79-101	154
873	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. 2017 , 102, 2770-2780	125
872	Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. 2017 , 116, 55-62	31
871	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. 2017 , 17, 471-478	23
870	Novel treatment options for anaplastic thyroid cancer. 2017 , 12, 279-288	10
869	PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma. 2017 , 44, 740-746	24
868	Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma. 2017 , 71, 16-25	30
867	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. 2017 , 9,	167
866	PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1. 2017 , 20, 917-926	84
865	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. 2017 , 18, 33	9
864	B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. 2017 , 23, 5202-5209	65
863	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. 2017 , 16, 1705-1717	36
862	Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. 2017 , 22, 631-637	60

861	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. 2017 , 99, 153-164	52
860	Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. 2017 , 6, e1304337	12
859	A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. 2017 , 19, 1874-1887	74
858	Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer. 2017 , 13, 4818-4824	8
857	Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. 2017 , 18, 1061-1079	3
856	Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model. 2017 , 23, 5502-5513	24
855	Immunomodulation for glioblastoma. 2017 , 30, 361-369	14
854	Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. 2017 , 77, 843-857	32
853	Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome. 2017 , 28, 54-59	8
852	PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis. 2017 , 95, 133-138	6
851	Pembrolizumab for the treatment of non-small cell lung cancer. 2017 , 17, 399-409	24
850	Immunotherapy in malignant melanoma: recent approaches and new perspectives. 2017 , 4, 39-48	6
849	Cytoreductive nephrectomy in the era of targeted therapies: a review. 2017 , 120, 320-328	18
848	CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. 2017 , 7, 737	387
847	Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches. 2017 , 331, 289-383	37
846	Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. 2017 , 8, 14754	185
845	PD-1/PD-L1 Pathway in Breast Cancer. 2017 , 40, 294-297	60
844	Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. 2017 , 66, 877-890	93

843	Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone. 2017 , 28, 493-509	11
842	Effect of EB13 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway. 2017 , 39, 1010428317692237	7
841	Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1. 2017 , 13, 892-900	18
840	Low hepatitis B virus-specific T-cell response in males correlates with high regulatory T-cell numbers in murine models. 2017 , 66, 69-83	28
839	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. 2017 , 132, 359-372	7
838	Biomarkers and Immunotherapeutic Targets in Glioblastoma. 2017 , 102, 494-506	19
837	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. 2017 , 76, 152-166	62
836	Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?. 2017 , 129, 275-279	67
835	The emerging role of immune checkpoint inhibition in malignant lymphoma. 2017 , 102, 30-42	81
834	The network of immunosuppressive pathways in glioblastoma. 2017 , 130, 1-9	56
833	Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC). 2017 , 8, 73-79	14
832	Expression of programmed cell death-1 and its ligand B7 homolog 1 in peripheral blood lymphocytes from patients with peripartum cardiomyopathy. 2017 , 40, 307-313	6
831	Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. 2017 , 6, 40-48	53
830	T Cell Exhaustion in Glioblastoma: Intricacies of Immune Checkpoints. 2017 , 38, 104-115	64
829	Markers and function of human NK cells in normal and pathological conditions. 2017 , 92, 100-114	83
828	Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. 2017 , 222, 651-657	34
827	Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer. 2017 , 23, 3453-3460	41
826	Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment. 2017 , 50, 41-48	49

825	T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. 2017 , 102, 562-572	89
824	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. 2017 , 7, 14049	27
823	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. 2017 , 33-35, 23-35	15
822	Frontiers in Ovarian Cancer Science. 2017 ,	1
821	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. 2017 , 77, 6667-6678	79
820	A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma. 2017 , 37, 1391-1405	11
819	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. 2017 , 18, 1483-1492	688
818	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. 2017 , 119, 30-39	29
817	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. 2017 , 119, 1-12	105
816	Hypothesis: stimulation of trained immunity as adjunctive immunotherapy in cancer. 2017 , 102, 1323-1332	24
815	Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms. 2017 , 322, 1-14	71
814	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 2017 , 17, 1055-1069	19
813	Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. 2017 , 8,	42
812	Anti-PD1/PDL1 induced psoriasis. 2017 , 41, 407-412	61
811	Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness. 2017 , 1868, 571-583	34
810	Merkel Cell Polyomavirus: A New DNA Virus Associated with Human Cancer. 2017 , 1018, 35-56	6
809	Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. 2017 , 28, xii44-xii55	100
808	MicroRNA-155 induction via TNF- α and IFN- β suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells. 2017 , 292, 20683-20693	77

807	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. 2017 , 77, 1645-1655	4
806	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). 2017 , 84, 202-211	25
805	Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer. 2017 , 23, 5394-5405	48
804	Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors. 2017 , 23, 6982-6992	169
803	Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. 2017 , 24, T261-T281	30
802	Enhanced expression of PD-L1 and IFN- γ dendritic cells is associated with BCG-induced Th2 inhibition. 2017 , 99, 163-172	9
801	Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining. 2017 , 125, 908-917	8
800	CD155T/TIGIT Signaling Regulates CD8 T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. 2017 , 77, 6375-6388	121
799	Advances in immunotherapy in multiple myeloma. 2017 , 29, 460-466	12
798	Second-line systemic therapy in metastatic renal-cell carcinoma: A review. 2017 , 35, 640-646	11
797	Emerging immunotherapy in advanced renal cell carcinoma. 2017 , 35, 687-693	10
796	Are programmed cell death 1 gene polymorphisms correlated with susceptibility to rheumatoid arthritis?: A meta-analysis. 2017 , 96, e7805	12
795	The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis. 2017 , 86, 361-367	30
794	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. 2017 , 130, 2420-2430	174
793	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. 2017 , 9, 797-804	23
792	Role of PD-1 in Immunity and Diseases. 2017 , 410, 75-97	85
791	PD-L1 is an activation-independent marker of brown adipocytes. 2017 , 8, 647	65
790	New use of microsatellite instability analysis in endometrial cancer. 2017 , 14, 3297-3301	26

789	PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8 T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination. 2017 , 199, 3348-3359	44
788	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. 2017 , 50, 185-194	21
787	Localized CD47 blockade enhances immunotherapy for murine melanoma. 2017 , 114, 10184-10189	64
786	Case series of pleomorphic carcinomas of the lung treated with nivolumab. 2017 , 8, 724-728	35
785	Immunotherapy in genitourinary cancers: where are we going?. 2017 , 2, 73-78	2
784	Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer. 2017 , 20, 558-571	186
783	Galectin-1-Driven Tolerogenic Programs Aggravate Infection by Repressing Antibacterial Immunity. 2017 , 199, 1382-1392	17
782	Metastatic melanoma - a review of current and future drugs. 2012 , 2012, 212242	20
781	Incidence and Risk of Thyroid Dysfunction in Advanced or Metastatic Non-small Cell Lung Cancer Patients Treated with Pembrolizumab: A Meta-analysis. 2019 , 11, e5997	2
780	Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab. 2016 , 8, e631	19
779	Desbalances genéticos del locus 9p24.1 en pacientes argentinos con linfoma de Hodgkin clásico. 2021 , 34,	
778	Adjuvant Therapy options after Pelvic Exenteration for Advanced Rectal Cancer. 2021 , 194-204	
777	Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer. 2021 , 11, 684070	3
776	The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. 2021 , 22,	6
775	Microbial community alteration in tongue squamous cell carcinoma. 2021 , 105, 8457-8467	0
774	Characterization and function of circulating mucosal-associated invariant T cells and $\gamma\delta$ cells in oral lichen planus. 2021 ,	3
773	Targeting the tumor microenvironment of Ewing sarcoma. 2021 , 13, 1439-1451	0
772	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. 2021 , 9, 760211	0

771	Mechanisms of immune checkpoint inhibitor-mediated liver injury.. 2021 , 11, 3727-3739	5
770	Multiplexed imaging reveals an IFN- β -driven inflammatory state in nivolumab-associated gastritis. 2021 , 2, 100419	0
769	Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival. 2021 , 8, 745286	2
768	Tong-fu-li-fei decoction attenuates immunosuppression to protect the intestinal-mucosal barrier in sepsis by inhibiting the PD-1/PD-L1 signaling pathway. 2021 , 24,	0
767	Targeting the Gut Mucosal Immune System Using Nanomaterials. 2021 , 13,	1
766	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. 2021 , 9,	1
765	Long-Term Oral Administration of Piceatannol (3,5,3',4'-Tetrahydroxystilbene) Attenuates Colon Tumor Growth Induced by Azoxymethane Plus Dextran Sulfate Sodium in C57BL/6J Mice. 2021 , 1-12	2
764	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. 2021 ,	4
763	The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. 2021 , 101, 108220	1
762	Transplantation Immunobiology. 2009 , 1835-1866	1
761	Can childhood viral infection protect from type 1 diabetes?. 2009 , 119, 1458-61	1
760	'Exhaustive' look at PD-1/PDL-1 blockade in vivo. 2009 , 1, 525-7	1
759	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. 2010 , 1269-1318	
758	Adaptive Immunity. 2010 , 285-313	
757	Emerging Agents in Renal Cell Carcinoma. 2012 , 285-301	
756	Anti-PD-1 and Anti-B7-H1/PD-L1 Monoclonal Antibodies. 2012 , 291-306	
755	Regulation of Adaptive Immunity in the Elderly. 2012 , 1-23	
754	Development of Novel Anti-Cancer Immunotherapy Targeting Immune Evasion Mechanisms. 2012 , 61, 5-10	1

753 Signaling of Tumor-Induced Immunosuppression of Dendritic Cells. **2013**, 339-360

752 Anti-Programmed Death 1 (PD1). **2013**, 1-10

751 Dendritic Cells and Cancer: Development, Dysfunction and Therapeutic Targets. **2013**, 431-455

750 Host defenses to viruses. **2013**, 346-355

1

749 Hepatic Immunology. 13-25

748 Ethanol affects the absorption and tissue distribution of orally administered antigens in mice. **2013**, 56, 581-586

747 On the role of co-inhibitory molecules in dendritic cell: T helper cell coculture assays aimed to detect chemical-induced contact allergy. **2014**, 104, 115-35

2

746 Cancer Vaccines: Fundamentals and Strategies. **2014**, 163-185

745 Plant-Based Vaccines Against Pollen Allergy. **2014**, 243-264

744 Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer. **2014**, 435-462

743 The Emerging Role of Immunotherapy in Castrate-Resistant Prostate Cancer. **2014**, 121-137

742 Lymphocyte Activation Gene 3 (LAG-3). **2014**, 1-9

741 Encyclopedia of Medical Immunology. **2014**, 174-181

740 Overcoming Cancer Tolerance with Immune Checkpoint Blockade. **2015**, 87-129

739 Other New Agents for Hodgkin Lymphoma. **2015**, 355-361

738 Immunology of Pediatric Renal Transplantation. **2015**, 1-51

737 Emerging therapies. **2015**, 83-114

736 Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack. **2015**, 31-58

- 735 Emerging Agents in Renal Cell Carcinoma. **2015**, 385-402
- 734 Indoleamine 2,3-Dioxygenase-Competent Regulatory Dendritic Cells and Their Role in Alloimmune Regulation and Transplant Immune Tolerance. **2015**, 335-360
- 733 T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. **2015**, 231-244
- 732 Immunology of Pediatric Renal Transplantation. **2016**, 2457-2500
- 731 Systemic Treatment of Esophageal Cancer. **2016**, 325-344
- 730 Tumor Immunology and Immunotherapy in Cancer Patients. **2016**, 425-442 ○
- 729 Infectious and Immunological Aspects of Male Infertility. **2016**, 1-19
- 728 T cell co-stimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. ○
- 727 Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy. **2017**, 31-44
- 726 Neoplasms. **2017**, 279-296
- 725 Monoclonal Antibodies in Pediatric Acute Lymphoblastic Leukemia. **2017**, 201-237
- 724 Lipotoxicity in Non-parenchymal Liver Cells. **2017**, 1-21
- 723 PHENOTYPIC FEATURES OF T REGULATORY CELLS IN EARLY RHEUMATOID ARTHRITIS. **2017**, 54, 660-666 2
- 722 Immunotherapy for Renal Cell Cancer (RCC). **2017**, 295-317
- 721 Vaccine Therapy and Immunotherapy for Pancreatic Cancer. **2017**, 1-45
- 720 Infectious and Immunological Aspects of Male Infertility. **2017**, 1051-1069
- 719 Hodgkin lymphoma. **2017**, 205-222 ○
- 718 Immunotherapy related toxicities. **2017**, 11, 83-87 2

- 717 Role of Immune Checkpoint Proteins in Idiopathic Pulmonary Fibrosis.
- 716 REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. **2017**, 4, 51-65 1
- 715 Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer. **2017**, 13, 131-137
- 714 Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). **2018**, 365-396
- 713 Photoimmunotherapy for Cancer Metastasis Treatment. **2018**, 55-63
- 712 New Progress in Breast Cancer Immunotherapy. **2018**, 08, 47-52
- 711 Construction and Identification of Eukaryotic Expression Vector of Human Programmed Death Receptor 1. **2018**, 08, 55-60
- 710 FEATURES OF THE PHENOTYPE OF REGULATORY T CELLS IN EARLY AND ADVANCED RHEUMATOID ARTHRITIS. **2018**, 56, 423-428
- 709 Immune Checkpoint Inhibitors in the Treatment of Lymphomas. **2018**, 11, 303-312 7
- 708 Mechanisms of resistance to anti-Pd-1 therapy in metastatic cutaneous melanoma. **2018**, 17, 34-46 2
- 707 Effets endocriniens et métaboliques des immunothérapies anticancéreuses (d'après les recommandations de la Société Française d'Endocrinologie). **2018**, 202, 1947-1966
- 706 Cancer-Induced Immunosuppression can enable Effectiveness of Immunotherapy through Bistability Generation: a mathematical and computational Examination. 0
- 705 Novel Approaches to Immunotherapy in Triple Negative Breast Cancer. **2018**, In Press, 1
- 704 INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS. **2019**, 21, 59-68 1
- 703 Expressions and Clinical Significance of PD-L1 and PD-1 in Prostate Cancer. **2019**, 08, 9-14
- 702 Immunology of Melanoma. **2019**, 1-32
- 701 ??????????????????????. **2019**, 28, 3-9 2
- 700 Immune Landscape of Invasive Ductal Carcinoma Tumour Microenvironment Identifies a Prognostic and Immunotherapeutically Relevant Gene Signature.

- 699 Current Status and Future Direction of Immune Checkpoint Inhibitors. **2019**, 59, 217-223
- 698 Synergism of PDL/PD1 and IL33/ST2 Axis in Tumor Immunology. **2019**, 20, 223-228 2
- 697 Immunotherapy and Gliomas. **2020**, 251-265
- 696 Evolution of Response Criteria in Immunotherapy. **2020**, 7-11
- 695 Systemic Therapy for Esophageal Squamous Cell Carcinoma. **2020**, 2129, 321-333
- 694 Intrinsic disorder in the T cell receptor creates cooperativity and controls ZAP70 binding. 0
- 693 PD-L1hi plasmablasts limit the T cell response during the acute phase of parasite infections.
- 692 How to manage side effects of immunotherapy. **2020**, 14, 6-12
- 691 Expression and T cell Regulatory Action of the PD-1 Immune Checkpoint in the Ovary and Fallopian Tube. 0
- 690 Blockade of LAG-3 in PD-L1-deficient mice enhances clearance of blood stage malaria independent of humoral responses.
- 689 Non-Neoplastic Pathology of the Gastrointestinal Tract: A Practical Guide to Biopsy Diagnosis. **2020**, ,
- 688 Non-Neoplastic Diseases of the Anal Canal. **2020**, 434-445
- 687 Normal Oesophageal, Gastric and Duodenal Mucosa. **2020**, 131-156
- 686 Overcoming Cancer Tolerance with Immune Checkpoint Blockade. **2021**, 85-128
- 685 Biomarkers for Immune Checkpoint Inhibitors. **2021**, 449-463
- 684 Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives. **2021**, 13, 1
- 683 Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. **2021**, 12, 768957 1
- 682 The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia. **2021**, 14, 1

- 681 Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective. **2021**, 25, 10362-10375 4
- 680 Editorial: The Roles of Checkpoint Inhibitors in Inflammatory Diseases. **2021**, 12, 795495
- 679 Immunology of Melanoma. **2020**, 41-72
- 678 Correlation of genomic alterations and PD-L1 expression in thymoma. **2020**, 12, 7561-7570 2
- 677 PD-L1 [PD-1 interactions limit effector Treg cell populations at homeostasis and during infection. 0
- 676 Expression features of antigens involved in the formation of immunological synapse in splenic marginal zone lymphoma. **2020**, 15, 18-28
- 675 Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. **2020**, 8, 1647 5
- 674 Fundamentals of immunology for understanding immunotherapy for lymphoma. **2020**, 2020, 585-589 0
- 673 An Overview of Promising Biomarkers in Cancer Screening and Detection. **2020**, 20, 831-852 1
- 672 Synergy of Immunotherapy and Radiosurgery. **2020**, 355-369
- 671 T Cell Exhaustion Could Be Regulating by Yangyin Fuzheng Decoction in Lewis Lung Cancer in a Tumor Burdened Mice. **2020**, 10, 31-40
- 670 Exciting progress of cancer immunotherapy focusing on immune checkpoints. **2020**, 185, 03007
- 669 Immunopathology and Immunotherapy of Hodgkin Lymphoma. **2020**, 135-157
- 668 Immunopathology and Immunotherapy for Breast Cancer. **2020**, 541-555 0
- 667 Encyclopedia of Pathology. **2020**, 1-8
- 666 Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience. **2020**, 11, 150-157
- 665 Identification of the cis-molecular neighbours of the immune checkpoint protein B7-H4 in the breast cancer cell-line SK-BR-3 by proteomic proximity labelling. **2020**, 57, 87-99 0
- 664 Galectin-1 Cooperates with Yersinia Outer Protein (Yop) P to Thwart Protective Immunity by Repressing Nitric Oxide Production. **2021**, 11, 0

663	Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression. 2021 , 10,	0
662	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. 2021 , 12, 764138	6
661	PD-L1-expressing astrocytes act as a gate-keeper for neuroinflammation in the central nervous system of mice with traumatic brain injury.	0
660	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. 2021 , 6, eabf4034	2
659	An Immunogold Single Extracellular Vesicular RNA and Protein (AuSERP) Biochip to Predict Responses to Immunotherapy in Non-Small Cell Lung Cancer Patients.	0
658	Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial. 2021 , 1	4
657	Approach to Reporting Inflammatory Bowel Disease Biopsies. 2020 , 401-409	0
656	Ileal Pouch Anal Anastomosis. 2020 , 410-416	
655	Diverticular Disease, Mucosal Prolapse, and Related Conditions. 2020 , 417-433	
654	Drug-Induced Gastrointestinal Disease. 2020 , 65-83	
653	Duodenitis. 2020 , 206-214	
652	Inflammatory Bowel Disease Diagnosis. 2020 , 325-356	1
651	Index. 2020 , 446-462	
650	Complications of Inflammatory Bowel Disease. 2020 , 388-400	
649	PD-L1 lncRNA splice promotes lung adenocarcinoma progression via enhancing c-Myc activity.	
648	Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma. 2020 , 111, 337-343	1
647	Simultaneous, cell-intrinsic downregulation of PD-1 and TIGIT enhances the effector function of CD19-targeting CAR T cells and promotes an early-memory phenotype.	
646	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors. 2020 , 14, 205-212	

645	Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma. 2021 , 17, 280-288	1
644	Dendritic cell modulation as a new interventional approach for the treatment of asthma. 2009 , 22, 445-51	8
643	Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. 2011 , 84, 409-21	90
642	T cell costimulation and coinhibition: genetics and disease. 2011 , 12, 119-28	16
641	Role of biphasic changes in splenic dendritic cell activity in a mouse model of multiple organ dysfunction syndrome. 2014 , 7, 4720-33	1
640	PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes. 2015 , 8, 1374-83	3
639	Correlation study of Bcl-2, B7-H1, EGFR, VEGF and colorectal cancer. 2015 , 5, 2277-84	5
638	Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. 2015 , 8, 9351-9	21
637	Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population. 2015 , 8, 16585-91	26
636	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. 2016 , 4, 1-8	20
635	Immunotherapy for lung cancer: advances and prospects. 2016 , 5, 1-20	26
634	Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis. 2016 , 8, 3274-87	33
633	Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells. 2017 , 81, 147-154	2
632	[Progress of PD-1/PD-L1 Inhibitors in Non-small Cell Lung Cancer]. 2017 , 20, 138-142	
631	[Progress in immunotherapy for non-small cell lung cancer]. 2014 , 17, 34-41	0
630	[Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer]. 2015 , 18, 706-13	
629	New advances in immunotherapy for non-small cell lung cancer. 2018 , 10, 2234-2245	23
628	The expression of PD-1 and LAG-3 in periapical lesions. 2018 , 10, 2677-2684	3

627	Regulatory T Cells in Gynecologic Cancer. 2018 , 6, 34-42	11
626	Immune mechanisms of idiosyncratic drug-induced liver injury. 2017 , 3, 145-156	15
625	Immune reaction by cytoreductive prostatectomy. 2019 , 7, 64-79	2
624	[New Advances in the Treatment for Small Cell Lung Cancer]. 2019 , 22, 355-362	0
623	Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer. 2019 , 18, 2661-2669	2
622	[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer]. 2019 , 22, 440-448	
621	[Recommendation of Diagnosis and Management for the Infections Related to Immune Checkpoint Inhibitors]. 2019 , 22, 666-670	
620	Combined induction with anti-PD-1 and anti-CTLA-4 antibodies provides synergistic antitumor effects in DC-CIK cells in renal carcinoma cell lines. 2019 , 12, 123-132	4
619	Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer. 2019 , 12, 774-786	6
618	Bone marrow PD-1 positive T cells reflect tumor mass and prognosis in multiple myeloma. 2018 , 11, 304-313	7
617	High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer. 2018 , 11, 2675-2682	3
616	Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features. 2017 , 10, 10565-10570	
615	The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis. 2017 , 75, 155-163	1
614	[Soluble programmed death-1 and soluble programmed death ligand 1 protein expression and immune status in patients with recurrent aphthous ulcer]. 2017 , 35, 286-290	2
613	[Advances on PD-1/PD-L1 inhibitors in multiple myeloma]. 2018 , 39, 261-264	
612	[Role of programmed death-1 in viral infectious diseases]. 2018 , 20, 77-82	1
611	IFN γ and TNF α synergistically promote galectin 9 secretion by human osteosarcoma cells MG-63 to prevent T cell killing. 2020 , 13, 2009-2017	
610	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. 2017 , 15, 466-477	3

609	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. 2017 , 15, 543-551	4
608	Synergistic effect of programmed death-1 inhibitor and programmed death-1 ligand-1 inhibitor combined with chemotherapeutic drugs on DLBCL cell lines and. 2020 , 10, 2800-2812	4
607	Use of dual-transfection for programmed death cell protein 1 disruption mediated by CRISPR-Cas9 in human peripheral blood mononuclear cells. 2021 , 24, 44-50	
606	AKIP1 promotes glioblastoma viability, mobility and chemoradiation resistance via regulating CXCL1 and CXCL8 mediated NF- κ B and AKT pathways. 2021 , 11, 1185-1205	3
605	[Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine ?in Attenuating the Related Mortality in Mice]. 2021 , 24, 394-403	1
604	Emerging role of PD-L1 modification in cancer immunotherapy. 2021 , 11, 3832-3840	2
603	The Concept of Co-Stimulatory Blockade in SLEplease remove Aff4. 2021 , 97-108	
602	Systemic Therapy of Advanced Melanoma. 2021 , 219-237	
601	The potential role of exosomal circRNAs in the tumor microenvironment: insights into cancer diagnosis and therapy.. 2022 , 12, 87-104	4
600	Immunopharmacogenomics: a hope in the treatment of carcinoma. 2022 , 327-346	
599	The Epithelial-Stromal Microenvironment in Early Colonic Neoplasia. 2021 ,	0
598	Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives. 2021 , 23, 428-435	
597	Heterogeneity analysis of the immune microenvironment in laryngeal carcinoma revealed potential prognostic biomarkers. 2021 ,	2
596	PD-L1 is expressed on human activated naive effector CD4+ T cells. Regulation by dendritic cells and regulatory CD4+ T cells. 2021 , 16, e0260206	0
595	What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). 2021 , 22,	7
594	Explore association of genes in PDL1/PD1 pathway to radiotherapy survival benefit based on interaction model strategy. 2021 , 16, 223	1
593	The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis. 2021 , 11, 759497	0
592	Increased soluble programed cell death-ligand 1 is associated with acute coronary syndrome. 2021 ,	0

591	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. 2021 , 19, 117	2
590	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via an ICOS-dependent mechanism. 2021 ,	1
589	The role of complement in the tumor microenvironment.. 2021 , 10, 80	0
588	Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.. 2021 , 10,	2
587	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. 2021 , 12, 777073	0
586	Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. 2021 , 13,	4
585	Fractional Laser Treatment Boosts Systemic Anti-Tumor Immunity in Combination with OX40 Agonist and PD-1 Blockade.	
584	Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.. 2022 ,	1
583	Pulmonary Toxicities of Immunotherapy.. 2021 , 1342, 357-375	
582	Research Progress of PD-1/PD-L1 Inhibitors in Neoimmunoadjuvant Therapy of Esophageal Cancer. 2021 , 11, 5106-5111	0
581	The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.. 2022 , 12, 36	0
580	Electrostimulus-associated PD-L1 expression on cell membrane revealed by immune SERS nanoprobe.. 2022 ,	1
579	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.. 2022 , 2, 55-63	0
578	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.. 2021 , 12, 810388	4
577	Association between clinicopathological features and prognosis significance of PD-L1 expression in small cell lung cancer patients: a systemic review and meta-analysis.. 2020 , 9, 5508-5516	
576	Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy.. 2020 , 9, 7310-7322	
575	Vibration properties of immune-oncological drugs.	
574	Programmed cell death ligand 1 expression in aggressive pediatric non-Hodgkin lymphomas: frequency, genetic mechanisms, and clinical significance.. 2022 ,	1

573	A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy.. 2022 , 2022, 8537966	0
572	Preclinical Pharmacokinetics and Dosimetry of an Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model.. 2021 , 8, 741855	
571	Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.. 2022 , 1	0
570	The Role of the Immune Checkpoint Molecules PD-1/PD-L1 and TIM-3/Gal-9 in the Pathogenesis of Preeclampsia-A Narrative Review.. 2022 , 58,	1
569	Vitamin D can reduce severity in COVID-19 through regulation of PD-L1.. 2022 ,	0
568	Comparison of the tumor microenvironments of squamous cell carcinoma at different anatomical locations within the upper aerodigestive tract in relation to response to ICI therapy.. 2022 , 11, e1363	0
567	Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma.. 2022 , 20, 9	1
566	Sintilimab-induced autoimmune diabetes: A case report and review of the literature.. 2022 , 10, 1263-1277	0
565	Blocking the inhibitory receptor PD-1 prevents allergic immune response and anaphylaxis in mice.. 2022 ,	0
564	The Renaissance of Cyclin Dependent Kinase Inhibitors.. 2022 , 14,	6
563	PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.. 2022 ,	1
562	PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.. 2022 , 1	1
561	Biomarkers related to immune checkpoint inhibitors therapy.. 2022 , 112470	1
560	PARP mediated DNA damage response, genomic stability and immune responses.. 2021 ,	3
559	Inflammatory Thoracic Aortic Aneurysm in a Patient with Advanced Lung Adenocarcinoma Treated with Pembrolizumab.. 2022 ,	0
558	Perspectives on the role of breast cancer susceptibility gene in breast cancer.. 2022 , 27, 495	
557	C57BL/6 Mice Pretreated With Alpha-Tocopherol Show a Better Outcome of Infection With Less Tissue Inflammation and Fibrosis.. 2022 , 13, 833560	
556	Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack.. 2022 , 119,	1

555	Tumor-Infiltrating PD-1+ Immune Cell Density is Associated with Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer.. 2022 ,	2
554	New Therapeutic Approaches for Conjunctival Melanoma-What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells.. 2022 , 23,	0
553	Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity.. 2022 , 58,	1
552	Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA, LUAD and STAD.. 2022 , 23, 1	0
551	Characterization of Leptin Receptor Stromal Cells in Lymph Node.. 2021 , 12, 730438	
550	Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.. 2022 ,	2
549	Self-blockade of PD-L1 with bacteria-derived outer-membrane vesicle for enhanced cancer immunotherapy. 2021 , e2106307	5
548	Traditional Chinese Medicine Pien-Tze-Huang Inhibits Colorectal Cancer Growth and Immune Evasion by Reducing β catenin Transcriptional Activity and PD-L1 Expression.. 2022 , 13, 828440	1
547	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.. 2022 , 1	
546	Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor.. 2022 , 55, 25-35	0
545	Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.. 2022 , 5, 147-164	0
544	HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma.. 2022 , 10,	0
543	PD-L1 signaling in reactive astrocytes counteracts neuroinflammation and ameliorates neuronal damage after traumatic brain injury.. 2022 , 19, 43	2
542	Immunosuppressive Properties of Epidermal Keratinocytes Differ According to Their Immaturity Status.. 2022 , 13, 786859	
541	Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials.. 2022 , 7, 100396	2
540	Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.. 2022 , 12, 769124	2
539	Behandlung rheumatischer immunbedingter Nebenwirkungen bei der Krebsimmuntherapie mit Immun-Checkpoint-Inhibitoren Ist es Zeit für einen Paradigmenwechsel?. 1-8	
538	PD-L1 Expression Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in Oral SCC.. 2022 , 12,	1

537	Inhibition of the Na/K-ATPase by cardiac glycosides suppresses expression of the IDO1 immune checkpoint in cancer cells by reducing STAT1 activation.. 2022 , 101707	4
536	PD-1/PD-L1, Treg-related proteins, and tumour-infiltrating lymphocytes are associated with the development of oral squamous cell carcinoma. 2021 ,	7
535	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. 2021 , 12, 598	3
534	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. 2020 , 45,	6
533	Effects of PD-1 Signaling on Immunometabolic Reprogramming.. 2022 , 4,	0
532	Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.. 2022 , 113, 1-57	0
531	Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway.. 2022 , 18, 2419-2438	0
530	MicroRNAs as potential immunotherapeutic modulators in cancer. 2022 , 165-183	
529	Clinical Relevance of PD-L2 Expression in Surgically Resected Lung Adenocarcinoma.	
528	Hepatocellular carcinoma stem cells, progression and therapy. 2022 , 97-107	0
527	Human placental exosomes induce maternal systemic immune tolerance by reprogramming circulating monocytes.. 2022 , 20, 86	4
526	Cell membrane coated-nanoparticles for cancer immunotherapy. 2022 ,	6
525	Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?. 2022 , 11,	0
524	Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy. 2022 ,	
523	Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy.. 2022 , 12, 847350	1
522	Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. 2022 , 3, 68-83	0
521	Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective.. 2022 , 23, 268	1
520	PD-L1 blockade liberates intrinsic antitumorigenic properties of glycolytic macrophages in hepatocellular carcinoma.. 2022 ,	1

519	Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma. 2022 , 16, 10-15	
518	T-cells of invasive candidiasis patients show patterns of T-cell-exhaustion suggesting checkpoint blockade as treatment option.. 2021 ,	1
517	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.. 2022 , 15, 24	8
516	Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia.. 2022 , 11, 11	3
515	Expression Profile of Selected Antitumor Immune Response Genes in Pediatric Classic Hodgkin Lymphoma.. 2022 ,	
514	A review of pathobiology and therapies for classic Hodgkin lymphoma.. 2022 , 100949	0
513	The Role of Metabolic Dysfunction in T-Cell Exhaustion During Chronic Viral Infection.. 2022 , 13, 843242	1
512	Long-term T cell perturbations and waning antibody levels in individuals needing hospitalization for COVID-19.	0
511	Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.. 2022 , 13, 827921	4
510	Elucidation of natural compounds Gallic acid and Shikonin for the treatment of HNSC cancer by targeting immune suppressor and tumour progressor genes. 1	
509	Immunomodulatory role of thrombin in cancer progression.. 2022 ,	0
508	Innate PD-L1 limits T cell-mediated adipose tissue inflammation and ameliorates diet-induced obesity.. 2022 , 14, eabj6879	1
507	Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.. 2022 , 13, 848327	0
506	Advances in the Pathomechanisms of Delayed Drug Hypersensitivity.. 2022 , 42, 357-373	0
505	Neuroinflammation creates an immune regulatory niche at the meningeal lymphatic vasculature near the cribriform plate.. 2022 ,	4
504	Anti-tumor immunity and ferroptosis of hepatocellular carcinoma are enhanced by combined therapy of sorafenib and delivering modified GO-based PD-L1 siRNAs. 2022 , 212761	
503	The Programmed Death-1 Pathway Counter-Regulates Inflammation-Induced Osteoclast Activity in Clinical and Experimental Settings.. 2022 , 13, 773946	2
502	The effects of immune checkpoint modulators on the clinical course of patients with resectable hepatocellular carcinoma. 2022 , 22, 40-50	

501	Immune Checkpoint Receptors Signaling in T Cells.. 2022 , 23,	1
500	Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.. 2022 , 1	1
499	Adipose-derived stem cells ameliorate atopic dermatitis by suppressing the IL-17 expression of Th17 cells in an ovalbumin-induced mouse model.. 2022 , 13, 98	0
498	Tumor-Mediated Neutrophil Polarization and Therapeutic Implications.. 2022 , 23,	0
497	Phase Ib study of durvalumab (MEDI4736) in combination with carbon-ion radiotherapy and weekly cisplatin for patients with locally advanced cervical cancer (DECISION study): study protocol for a prospective open-label single-arm study.. 2022 , 12, e056424	0
496	Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer.. 2022 ,	0
495	Cellular vesicles expressing PD-1-blocking scFv reinvigorate T cell immunity against cancer. 1	0
494	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies.. 2022 , 10,	1
493	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition.. 2022 , 10,	0
492	Efficacy of Camrelizumab in Advanced Non-Small-Cell Lung Cancer and Prognostic Analysis of Different PET/CT Features.. 2022 , 2022, 9942918	
491	PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases.. 2022 , 13, 854967	2
490	An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy.. 2022 ,	1
489	Immune Checkpoint Inhibitor Exposure in Pregnancy: A Scoping Review.. 2022 ,	0
488	PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma.. 2022 ,	
487	Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant NSCLC.. 2022 ,	1
486	Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.. 2022 , 1	
485	How to overcome tumor resistance to anti-PD-1/PD-L1 therapy by immunotherapy modifying the tumor microenvironment in MSS CRC.. 2022 , 108962	1
484	High Expression of RAI14 in Triple-Negative Breast Cancer Participates in Immune Recruitment and Implies Poor Prognosis Through Bioinformatics Analyses.. 2022 , 13, 809454	1

- 483 Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy.. **2022**, 13, 838966 0
- 482 Macrophage and T-Cell Infiltration and Topographic Immune Cell Distribution in Non-Melanoma Skin Cancer of the Head and Neck.. **2022**, 12, 809687
- 481 An evaluation of pembrolizumab for classical Hodgkin lymphoma.. **2022**, 1-9
- 480 Programmed death receptor ligand-2 (PD-L2) bearing extracellular vesicles as a new biomarker to identify early triple-negative breast cancer patients at high risk for relapse.. **2022**, 0
- 479 Nanodrug shows spatiotemporally controlled release of anti-PD-L1 antibody and STING agonist to effectively inhibit tumor progression after radiofrequency ablation. **2022**, 43, 101425 2
- 478 Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.. **2022**, 7
- 477 The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden.. **2022**, 153, 155839 0
- 476 Synthesis and biological evaluation of Al[F]-NOTA-IPB-PDL1P as a molecular probe for PET imaging of PD-L1 positive tumors.. **2022**, 122, 105682 0
- 475 An overview of immune checkpoint therapy in autoimmune diseases.. **2022**, 107, 108647 0
- 474 Toxicity profile of treatment with PD-1 inhibitors for lung cancer, melanoma and renal cell carcinoma: A real-world Brazilian study.. **2022**, 108, 108727
- 473 Current methods and emerging approaches for detection of programmed death ligand 1.. **2022**, 208, 114179 0
- 472 Remodeling tumor immunosuppressive microenvironment via a novel bioactive nanovaccines potentiates the efficacy of cancer immunotherapy.. **2022**, 16, 107-119 2
- 471 Immunotherapy in Patients with Advanced Non-Small Cell Lung Cancer Lacking Driver Mutations and Future Perspectives.. **2021**, 14, 2
- 470 The multi-specific V-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.. **2021**, 1
- 469 Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.. **2021**, 22, 2
- 468 Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma. **2021**, 22, 0
- 467 Neutrophil Expression of T and B Immunomodulatory Molecules in HIV Infection.. **2021**, 12, 670966 1
- 466 Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy.. **2021**, 11, 1

465	Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. 2021 , 3, 84-94	
464	Enhancer RNA-based modeling of adverse events and objective responses of immunotherapy.	
463	Reversing T-cell Exhaustion in Cancer: Lessons Learned from PD-1/PD-L1 Immune Checkpoint Blockade.. 2021 ,	8
462	Skin Immunity and Tolerance: Focus on Epidermal Keratinocytes Expressing HLA-G.. 2021 , 12, 772516	2
461	Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy. 2021 ,	2
460	CMTM6: Increased Circulating Level and Up-regulated Expression in Labial Salivary Glands in Patients with Primary Sjogren's Syndrome.. 2021 ,	
459	Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis.. 2021 , 11,	1
458	Immunotherapy Resistance in Glioblastoma.. 2021 , 12, 750675	1
457	The Monoclonal Antibody Pembrolizumab Alters Dynamics of the Human Programmed Cell Death Receptor 1 (PD-1). 2021 ,	0
456	Head and Neck Squamous Cell Carcinoma: Risk Factors, Molecular Alterations, Immunology and Peptide Vaccines.. 2022 , 28, 19	5
455	Prognostic value of programmed death ligand 1 (PD-L1) in glioblastoma: a systematic review, meta-analysis and validation based on dataset.. 2021 , 12, 10366-10378	1
454	A Novel Small Cyclic Peptide-Based Ga-Radiotracer for Positron Emission Tomography Imaging of PD-L1 Expression in Tumors.. 2022 , 19, 138-147	1
453	A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.. 2021 , 12, 778978	1
452	Expression of programmed cell death ligand-1 protein in germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.. 2022 , 16, 42	
451	The expression and function of programmed death-ligand 1 and related cytokines in neutrophilic asthma.. 2021 , 9, 1727	0
450	Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. 2021 , 12, CD011300	1
449	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism.. 2022 , 13, 835510	1
448	Triggers Antitumor Immunity by Restricting PD-1 Expression of CD8 T Cells in Local Tumor Microenvironment.. 2022 , 13, 774440	0

- 447 T cell cholesterol efflux suppresses apoptosis and senescence and increases atherosclerosis in middle aged mice.
- 446 Recent advances in organic and polymeric carriers for local tumor chemo-immunotherapy. **2022**, 65, 1011 1
- 445 Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma.. **2022**, 12, 815917 0
- 444 Intermediate Monocytes with PD-L1 and CD62L Expression as a Possible Player in Active SARS-CoV-2 Infection.. **2022**, 14, 0
- 443 Clinicopathological Features of Gastric Cancer with Autoimmune Gastritis.. **2022**, 10, 1
- 442 PD-L1 signaling selectively regulates T cell lymphatic transendothelial migration.. **2022**, 13, 2176 1
- 441 Modulating Tumor Physical Microenvironment for Fueling CAR-T Cell Therapy.. **2022**, 114301 1
- 440 Data_Sheet_1.docx. **2019**,
- 439 Data_Sheet_1.pdf. **2020**,
- 438 Image_1.TIF. **2018**,
- 437 Image_2.TIF. **2018**,
- 436 Image_3.TIF. **2018**,
- 435 Data_Sheet_1.pdf. **2020**,
- 434 Data_Sheet_1.docx. **2020**,
- 433 presentation_1.PDF. **2018**,
- 432 image_1.TIF. **2018**,
- 431 image_2.TIF. **2018**,
- 430 image_3.TIF. **2018**,

429 image_4.TIF. **2018,**

428 image_5.TIF. **2018,**

427 Data_Sheet_1.PDF. **2019,**

426 Data_Sheet_2.xlsx. **2019,**

425 Data_Sheet_1.docx. **2018,**

424 Image_1.jpeg. **2020,**

423 Image_2.tif. **2020,**

422 Image_1.tiff. **2018,**

421 Video_1.MP4. **2018,**

420 Video_2.MP4. **2018,**

419 image_1.tif. **2018,**

418 image_2.tif. **2018,**

417 image_3.tif. **2018,**

416 image_4.tif. **2018,**

415 video_1.wmv. **2018,**

414 Image_1.jpeg. **2018,**

413 Image_3.jpeg. **2018,**

412 Image_4.jpeg. **2018,**

411 Image_5.jpeg. 2018,

410 Image_6.jpeg. 2018,

409 DataSheet_1.docx. 2020,

408 Data_Sheet_1.docx. 2020,

407 DataSheet_1.pdf. 2020,

406 Table_1.xlsx. 2020,

405 Image_1.jpeg. 2018,

404 Image_2.JPEG. 2018,

403 Image_3.JPEG. 2018,

402 Image_4.JPEG. 2018,

401 Image_5.JPEG. 2018,

400 DataSheet_1.pdf. 2020,

399 DataSheet_2.pdf. 2020,

398 Image_1.tif. 2018,

397 Image_2.tif. 2018,

396 Table_1.xlsx. 2018,

395 DataSheet_1.docx. 2021,

394 Image_1.PDF. 2018,

393 Image_2.PDF. 2018,

392 Image_3.PDF. 2018,

391 Image_4.PDF. 2018,

390 Image_5.PDF. 2018,

389 Table_1.DOCX. 2018,

388 Table_2.DOCX. 2018,

387 Table_1.DOCX. 2020,

386 Table_2.DOCX. 2020,

385 Image1.PDF. 2018,

384 Image2.PDF. 2018,

383 Image3.PDF. 2018,

382 Image4.PDF. 2018,

381 Presentation1.pdf. 2018,

380 Table1.PDF. 2018,

379 Table2.PDF. 2018,

378 Table3.PDF. 2018,

377 Table_1.DOCX. 2020,

376 Data_Sheet_1.docx. 2019,

375 DataSheet_1.docx. **2020**,

374 Image_1.TIF. **2019**,

373 Image_10.TIF. **2019**,

372 Image_2.TIF. **2019**,

371 Image_3.TIF. **2019**,

370 Image_4.TIF. **2019**,

369 Image_5.TIF. **2019**,

368 Image_6.TIF. **2019**,

367 Image_7.TIF. **2019**,

366 Image_8.TIF. **2019**,

365 Image_9.TIF. **2019**,

364 Table_1.XLSX. **2019**,

363 Table_1.XLSX. **2019**,

362 Data_Sheet_1.pdf. **2020**,

361 [Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation]. **2021**, 42, 869-877

360 Role of immune system in TNBC. **2022**, 121-148

359 Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma.. **2022**, 13, 869488

358 Assembly of Transmembrane Proteins from Expressed and Synthetic Components in Giant Unilamellar Vesicles.. **2022**, 17, 1015-1021

357	The ER-Mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors.. 2022 , 10, 867341	0
356	Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New.. 2022 , 1	
355	Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). 2022 , 15, 542	0
354	lncRNA EGFR-AS1 facilitates leiomyosarcoma progression and immune escape via the EGFR-MYC-PD-L1 axis.. 2022 ,	1
353	A novel PD-L1 targeting peptide self-assembled nanofibers for sensitive tumor imaging and photothermal immunotherapy in vivo. 1	0
352	Lack of Association Between Polymorphisms and Colorectal Cancer Risk: A Case-Control Study.. 2022 , 1-16	1
351	Advanced Materials for Management of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors. 2022 , 110738	
350	Programmed death ligand (PD-L1) expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy (CRT) for locally advanced rectal cancer.. 2022 ,	
349	Novel Insights Into the Immune-Regulatory Functions of Mast Cells in the Cutaneous Immune Response. 2022 , 13,	0
348	Multifunctional Nanosystems Powered Photodynamic Immunotherapy. 2022 , 13,	2
347	The Association of Programmed Death 1 Gene Polymorphisms of PD1.3 G/A and PD1.5 C/T with Risk of COVID-19 in an Iranian Population: A Case-Control Study.. 2022 ,	0
346	Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.. 2022 , 17, e0268288	1
345	An automated, rapid fluorescent immunoassay to quantify serum soluble programmed death-1 (PD-1) protein using testing-on-a-probe biosensors.. 2022 ,	0
344	The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma. 2022 , 12,	
343	Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.. 2022 , 168, 50-58	0
342	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.. 2022 , 108, 108803	0
341	Therapeutic bispecific antibodies against intracellular tumor antigens.. 2022 , 215699	2
340	Immunotherapy. 2022 , 243-280	

339	Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review).. 2022 , 60,	0
338	Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT).. 2022 , 1	
337	Phenotypic and functional characterizations of CD8 T cell populations in malignant pleural effusion.. 2022 , 113212	0
336	Extrafollicular Plasmablasts Present in the Acute Phase of Infections Express High Levels of PD-L1 and Are Able to Limit T Cell Response. 2022 , 13,	
335	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.. 2022 , 42, 1-14	1
334	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. 2022 , 10, 1181	1
333	The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. 2022 , 14, 2675	2
332	High-throughput virtual screening of small-molecule inhibitors targeting immune cell checkpoints to discover new immunotherapeutics for human diseases.	0
331	Cancers bronchiques non petites cellules (CNPC) rééables et immunothérapie : État des lieux et perspectives. 2022 , 14, 1S32-1S39	
330	The Molecular Role of IL-35 in Non-Small Cell Lung Cancer. 12,	
329	Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy. 2022 , 11, 1758	0
328	Characterization of the Immune Cell Infiltration Landscape Uncovers Prognostic and Immunogenic Characteristics in Lung Adenocarcinoma. 13,	1
327	Targeting protein kinases benefits cancer immunotherapy. 2022 , 188738	0
326	TERC suppresses PD-L1 expression by downregulating RNA binding protein HuR.	
325	Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN). 2022 , 14, 2782	0
324	Targeted therapies in non-small cell lung cancer and the potential role of AI interventions in cancer treatment.	0
323	Conscription of Immune Cells by Light-Activatable Silencing NK-Derived Exosome (LASNEO) for Synergetic Tumor Eradication. 2201135	3
322	An effective therapeutic regime for treatment of glioma using oncolytic Vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition. 2022 ,	0

321	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. 2022 , 16, 117955492210998	2
320	Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope. 2022 , 393-411	
319	Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. 2022 , 62, 49-63	1
318	Tumoral and Stromal Pdl1 and Pdl2 Checkpoints Immunohistochemical Expression in Pancreatic Ductal Adenocarcinoma, a Promising Field Of Study. 2022 , 10, 775-781	
317	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. 2022 , 17, 253-270	0
316	Exosome-Mediated Immunosuppression in Tumor Microenvironments. 2022 , 11, 1946	2
315	Blockade of TIM-3 and PD-1 enhances the antitumor effects of MAGE-A11 antigen-specific cytotoxic T lymphocytes. 2022 ,	
314	Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.	
313	Role of the PD-1/PD-L1 Pathway in Experimental Trypanosoma cruzi Infection and Potential Therapeutic Options. 13,	0
312	Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies. 2022 , 2022, 1-13	
311	PD-1/PD-L Axis in Neuroinflammation: New Insights. 13,	0
310	Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.	0
309	Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies. 12,	1
308	PD-L1 and PD-L2 mRNA measured using closed system qRT-PCR are associated with outcome and high negative predictive value in immunotherapy-treated non-small cell lung cancer. 2022 ,	0
307	The pharmacotherapeutic management of nail unit and acral melanomas. 1-17	2
306	An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and Glioblastoma Immunotherapy. 2022 , 121645	4
305	Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm. 12,	0
304	Macrophage PD-1 associates with neutrophilia and reduced bacterial killing in early cystic fibrosis airway disease. 2022 ,	0

- 303 Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. **2022**, 23, 101469
- 302 Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma. **2022**, 13, 204062072211033 0
- 301 Recent trends in cancer immunotherapy: Pathways and inhibitors. **2022**, 39-50
- 300 Research Progress of Chemokine and Costimulatory Molecules in the Pathogenesis of Mycoplasma pneumoniae Pneumonia in Children. **2022**, 12, 5937-5945
- 299 Recent Trends in the Integrated Management of Cutaneous Squamous Cell Carcinoma. **2022**, 2, 59-72 1
- 298 Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer. **2022**, 1
- 297 The Role of the Immune System in the Development of Endometriosis. **2022**, 11, 2028 2
- 296 Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment. **2022**, 13, 1
- 295 Tumor immunotherapy: Mechanisms and clinical applications. **2022**, 1,
- 294 Research progress in the PD-1/PD-L1 pathway and IL-17A in lymphomas. **2022**, 4, 38-45
- 293 Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer. **2022**, 2022, 1-10 0
- 292 A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma. **2022**, 2022, 1-27 1
- 291 Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. **2022**, 18, e1010673 0
- 290 Facts and Hopes in Immunotherapy of Pancreatic Cancer. OF1-OF12 3
- 289 The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers. 13,
- 288 Retrospective Study of Clinical Outcomes and Toxicity Profile in Patients Treated with Immune Checkpoint Inhibitors.
- 287 Ly6C hi monocytes balance regulatory and cytotoxic CD4 T cell responses to control virus-induced immunopathology. **2022**, 7, 1
- 286 Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma. 0

285	Genetics and therapeutic responses to TIL therapy of pancreatic cancer PDX models. 2022,	0
284	PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation.	1
283	Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. 10,	0
282	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. 28,	0
281	PD-1 and CTLA-4 exert additive control of effector regulatory T cells.	
280	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. 13,	
279	An Overview of Breast Cancer Therapy. 2022, 242-258	
278	Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial. 2022, 22,	0
277	Immune Checkpoint Inhibitors in Cancer TherapyHow to Overcome Drug Resistance?. 2022, 14, 3575	2
276	Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects. 2022, 10, e004863	1
275	Dexmedetomidine Attenuates LPS-Stimulated Alveolar Type II Cells Injury through Upregulation of miR-140-3p and Partial Suppression of PD-L1 Involving Inactivating JNK-Bnip3 Pathway. 2022, 2022, 1-11	
274	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. 2022, 1-20	
273	Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma. 2022, 12,	
272	Evolving Understanding of T-cell Cosignaling Pathways. 2022, 106, e388-e390	
271	Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. 2022, 13, 907-917	
270	Engineered immunomodulatory accessory cells improve experimental allogeneic islet transplantation without immunosuppression. 2022, 8,	3
269	Targetability of the neurovascular unit in inflammatory diseases of the central nervous system.	1
268	New Potential Immune Biomarkers in the Era of Precision Medicine: Lights and Shadows in Colorectal Cancer. 2022, 12, 1137	

267	Immunorthodontics: PD-L1, a Novel Immunomodulator in Cementoblasts, Is Regulated by HIF-1 β under Hypoxia. 2022 , 11, 2350	1
266	Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses. 13,	0
265	Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review. 12,	0
264	Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. 2022 , 14, 3860	
263	Molecular imaging to support cancer immunotherapy. 2022 , 10, e004949	0
262	Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis. 2022 ,	
261	T cell perturbations persist for at least 6 months following hospitalization for COVID-19. 13,	0
260	Importance of the endometrial immune environment in endometrial cancer and associated therapies. 12,	0
259	An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy. 2022 , 14,	0
258	Murine precursors to type 1 conventional dendritic cells induce tumor cytotoxicity and exhibit activated PD-1/PD-L1 pathway. 2022 , 17, e0273075	1
257	PD-L1 expression on circulating tumor cells can be a predictive biomarker to PD-1 inhibitors combined with radiotherapy and antiangiogenic therapy in advanced hepatocellular carcinoma. 12,	0
256	Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches. 2022 , 14, 1721	2
255	Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases. 2022 , 23, 8599	2
254	Islet allografts expressing a PD-L1 and IDO fusion protein evade immune rejection and reverse preexisting diabetes in immunocompetent mice without systemic immunosuppression.	
253	Clinical Significance of Negative Costimulatory Molecule PD-1/PD-L1 on Peripheral Blood Regulatory T Cell Levels among Patients with Pulmonary Tuberculosis. 2022 , 2022, 1-8	
252	Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment. 13,	
251	Establishment of CD8+ T cell thymic central tolerance to tissue-restricted antigen requires PD-1.	
250	Pregnancy Imparts Distinct Systemic Adaptive Immune Function.	0

- 249 PD-L1+ neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab. 13, 0
- 248 Efficacy and safety of pembrolizumab on cervical cancer: A systematic review and single-arm meta-analysis. 12, 0
- 247 Immunohistochemical Expression of Programmed Death Ligand 1 in Oral Extranodal Diffuse Large B Cell Lymphoma. 0
- 246 To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. **2022**, 188783 0
- 245 The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. 0
- 244 Proliferative tumor infiltrating lymphocytes abundance within microenvironment impact clinical outcome in cutaneous B-cell lymphomas. **2022**, 1
- 243 Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment. 0
- 242 Differential Expression of miRNA-192 is a Potential Biomarker for HIV Associated Immune Recovery Uveitis. 1-10 1
- 241 A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells. **2022**, 111, 109022 0
- 240 Discovery of the first PD-1 ligand encoded by a pathogen. 13, 0
- 239 Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report. 10, 10193-10200 0
- 238 Solid-type poorly differentiated adenocarcinoma of the stomach: A characteristic morphology reveals a distinctive immunoregulatory tumor microenvironment. **2022**, 238, 154124 0
- 237 Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. **2022**, 86, 14-27 2
- 236 STAT1 is associated with NK cell dysfunction by downregulating NKG2D transcription in chronic HBV-infected patients. **2022**, 227, 152272 0
- 235 NK cell immunometabolism as target for liver cancer therapy. **2022**, 112, 109193 0
- 234 Immune Tolerance at a Glance. **2022**, 27-44 0
- 233 Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. **2022**, 0
- 232 PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer. **2022**, 14, 14014-14022 0

231	Principles of Checkpoint Inhibition in Malignant Lymphoma. 2022,	0
230	Bioprospection and Clinical Investigations of Immunomodulatory Molecules. 2022, 53-81	0
229	Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo. 2022, 4,	0
228	Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics. 2022, 8, e10450	0
227	Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma.	0
226	MS4A6A is a new prognostic biomarker produced by macrophages in glioma patients. 13,	0
225	Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy. 2022, 10,	2
224	Pembrolizumab as a single agent for patients with MSI-H advanced endometrial carcinoma. 1-9	0
223	A comprehensive review of SHP2 and its role in cancer.	1
222	The relationship between PD-L1 and quiescence in melanocyte stem cell aging.	0
221	Virulence of Mycobacterium intracellulare clinical strains in a mouse model of lung infection [Role of neutrophilic inflammation in disease severity.	0
220	Association of gestational diabetes mellitus and negative modulation of the specific humoral and cellular immune response against Toxoplasma gondii. 13,	0
219	Anti-PD-1 Therapy is Beneficial for the Survival of Patients with Oral Squamous Cell Carcinoma. Volume 14, 2723-2731	0
218	Immunotherapy-Associated Uveitis.	0
217	Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. 2022, 11, 3028	2
216	PD-L1 enhances migration and invasion of trophoblasts by upregulating ARHGDI1B via transcription factor PU.1. 2022, 8,	0
215	Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma. 13,	0
214	Review: PD-L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer.	1

213	Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells. 2022 , 14, 4698	0
212	A Review of Current and Emerging Therapies for Advanced Hepatocellular Carcinoma. 2022 , 29, 6445-6462	0
211	Metabolic plasticity and regulation of T cell exhaustion.	0
210	Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment. 2022 ,	1
209	Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway. 2022 , 65, 11900-11912	0
208	Identification of key genes and mechanisms of epicardial adipose tissue in patients with diabetes through bioinformatic analysis. 9,	0
207	Quantitative Spatial Profiling of Immune Populations in Pancreatic Ductal Adenocarcinoma Reveals Tumor Microenvironment Heterogeneity and Prognostic Biomarkers.	0
206	High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood. 2022 , 10, 2405	0
205	An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. 2022 , 11,	1
204	Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. 13,	1
203	0.1% Nano-silver mediates PD-1/PD-L1 pathway and alleviates chronic apical periodontitis in rats.	0
202	Synthetic Biology Technologies And Genetically Engineering Strategies For Enhanced Cell Therapeutics.	0
201	Crosstalk between dendritic cells and regulatory T cells: Protective effect and therapeutic potential in multiple sclerosis. 13,	0
200	Mucosal-associated invariant T cells predict increased acute graft-versus-host-disease incidence in patients receiving allogeneic hematopoietic stem cell transplantation. 2022 , 22,	1
199	In Silico Inhibition of Three Cancer Inducing Receptors, IL-6, CTLA-4, and B7-2 by Dostarlimab may explain the 100% Complete Recovery Rate in MMRd Locally Advanced Rectal Cancer seen in Pivotal Immunoablative Neoadjuvant Immunotherapy Clinical Trial. A Cancer Therapy Breakthrough..	0
198	The new progress in cancer immunotherapy.	0
197	ATXN2-Mediated PI3K/AKT Activation Confers Gastric Cancer Chemoresistance and Attenuates CD8+ T Cell Cytotoxicity. 2022 , 2022, 1-16	0
196	Phenotypic and Transcriptional Changes of Pulmonary Immune Responses in Dogs Following Canine Distemper Virus Infection. 2022 , 23, 10019	1

195	In Silico Inhibition of three Cancer Inducing Receptors, IL-6, CTLA-4, and B7-2 by Dostarlimab may explain the 100% Complete Recovery Rate in MMRd Locally Advanced Rectal Cancer seen in Pivotal Immunoablative/Neoadjuvant Immunotherapy Clinical Trial. A Cancer Therapy Breakthrough..	0
194	Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGF β) provides significant antitumor efficacy in immune checkpoint resistant models. 2022 , 11,	0
193	Dual immunological and proliferative regulation of immune checkpoint FGL1 in lung adenocarcinoma: The pivotal role of the YY1/FGL1/MyH9 axis. 13,	0
192	PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression. 2022 , 13,	0
191	Anlotinib Benefits the PD-L1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer. 2022 , 2022, 1-18	0
190	A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy. 2022 ,	1
189	Immunology: How Does the Immune System Affect the Development of Pulmonary TB? How Does an Understanding of TB Immunology Help Clinicians Manage their Patients with Pulmonary TB?. 2022 , 33-58	0
188	Personalized Treatment in Immunotherapy for Gynecologic Cancer. 2022 , 77-85	0
187	Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals. 2022 , 23, 11623	0
186	Synthesis and preliminary evaluations of [18F]fluorinated pyridine-2-carboxamide derivatives for targeting PD-L1 in cancer. 2022 , 23,	0
185	Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. 2022 , 23, 12067	0
184	EBV-associated diseases: Current therapeutics and emerging technologies. 13,	1
183	Cell Component and Function of Tumor Microenvironment in Thyroid Cancer. 2022 , 23, 12578	0
182	Cancer Immunotherapy. 1-22	0
181	Emerging therapeutic options for periorbital and orbital cutaneous basal and squamous cell carcinomas. 1-7	0
180	The function and clinical implication of circular RNAs in lung cancer. 12,	0
179	Predictive biomarkers in gastric cancer.	1
178	Sex difference in the expression of PD-1 of non-small cell lung cancer. 13,	1

- 177 Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. **2022**, 23, 13241 ○
- 176 Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy. **2022**, 14, 5046 1
- 175 Current Status of Immune Checkpoint Inhibitors. **2022**, 73, 303-307 ○
- 174 Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities. **2022**, 10, 1673 ○
- 173 Malignant Melanoma. 1-27 ○
- 172 Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge. 2, ○
- 171 Study of PD-L1 Expression with Association of Pathological Factors and Molecular Subtypes in Breast Carcinoma. ○
- 170 EP400NL is involved in PD-L1 gene activation by forming a transcriptional coactivator complex. **2022**, 194889 ○
- 169 Microglial Extracellular Vesicles as Modulators of Brain Microenvironment in Glioma. **2022**, 23, 13165 ○
- 168 Programmed cell death 1 and programmed cell death ligand 1 expression in invasive breast carcinoma using CAL10 and NAT105 immunostaining. 1-8 ○
- 167 Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study. 12, ○
- 166 Rational design of a Nivolumab-based ANTI-PD-1 single chain variable fragment that INHIBITS the interaction between PD-1 expressed on T-CELLS and PD-L1 ON CHO cells. **2022**, 106196 ○
- 165 Role of non-coding RNA in immune microenvironment and anticancer therapy of gastric cancer. ○
- 164 Predictive value of tumor-infiltrating lymphocytes detected by flow cytometry in colorectal cancer. **2022**, 113, 109286 ○
- 163 The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. **2022**, 310, 121138 ○
- 162 Immunotherapy in gynecologic malignancies. **2023**, 506-520.e7 ○
- 161 Adjunctive PD-1 inhibitor versus standard chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis. **2022**, 14, 175883592211374 ○
- 160 The Correlation of Ten Immune Checkpoint Gene Expressions and Their Association with Gastric Cancer Development. **2022**, 23, 13846 ○

- 159 The role of costimulatory molecules in glioma biology and immune microenvironment. 13, ○
- 158 Research progress on the intrinsic non-immune function of PD-L1 in tumors (Review). 2022, 25, ○
- 157 Population dynamics and gene regulation of T cells in response to chronic antigen stimulation. ○
- 156 PD-L1 is upregulated in CD163+ tonsillar macrophages from children undergoing EBV primary infection. 13, ○
- 155 Single cell sequencing revealed the mechanism of PD-1 resistance affected by the expression profile of peripheral blood immune cells in ESCC. 13, ○
- 154 Inhibition of PD-1 Alters the SHP1/2-PI3K/Akt Axis to Decrease M1 Polarization of Alveolar Macrophages in Lung IschemiaReperfusion Injury. ○
- 153 Altered microRNA expression profile is linked to T-cell exhaustion-related pathways in pediatric patients with acute lymphoblastic leukemia. 2022, ○
- 152 Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy. ○
- 151 The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. 13, ○
- 150 Expression and Significance of Programmed Death-1 and Its Ligands in the Accelerated Formation of Atherosclerosis in an Induced Murine Lupus Model. 2022, 2022, 1-12 ○
- 149 PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?. 2022 , 103435 1
- 148 Emerging evidence of immunotherapy for colorectal cancer. ○
- 147 BSA-AIE nanoparticles with boosted ROS generation for immunogenic cell death immunotherapy of multiple myeloma. 2208692 ○
- 146 Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15R α complex. ○
- 145 Pathogenesis of giant cell arteritis with focus on cellular populations. 9, ○
- 144 Expression and T cell Regulatory Action of the PD-1 Immune Checkpoint in the Ovary and Fallopian Tube. ○
- 143 Atezolizumab plus tivozanib for immunologically cold tumor types: the 1MMCO-1 trial. ○
- 142 Immune checkpoint inhibitors as neoadjuvant therapy in early triple-negative breast cancer: A systematic review and meta-analysis. 2022, 18, 1754 ○

- 141 Immunotherapy and Targeted Therapy in the Management of Oral Cancers. **2022**, ○
- 140 Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. **2023**, 157, 114057 ○
- 139 Merkel Cell Polyomavirus (MCPyV). **2022**, 499-506 ○
- 138 Suppression of CD56^{bright} NK cells in breast cancer patients is associated with the PD-1 and TGF-βII expression. ○
- 137 The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients. **2022**, 14, 5757 1
- 136 Adverse Events of PD-1 or PD-L1 Inhibitors in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. **2022**, 12, 1990 ○
- 135 Canvassing Prospects of Glyco-Nanovaccines for Developing Cross-Presentation Mediated Anti-Tumor Immunotherapy. **2022**, 10, 2049 ○
- 134 Analysis of subgingival micro-organisms based on multi-omics and Treg/Th17 balance in type 2 diabetes with/without periodontitis. 13, ○
- 133 Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma. **2022**, 13, ○
- 132 Immune Checkpoints: The Rising Branch in Cancer Immunotherapy. ○
- 131 Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1. **2022**, 31, 1187-1202 ○
- 130 Divergent roles of PD-L1 in immune regulation during ischemia/reperfusion injury. 13, ○
- 129 B7 family protein glycosylation: Promising novel targets in tumor treatment. 13, ○
- 128 The origin of regulatory from the effector cells in LAG-3-marked Th1 immunity against severe influenza virus infection. ○
- 127 Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy. **2022**, 12, 2104 1
- 126 Inborn errors of immunity associated with defects of self-tolerance checkpoints: The CD28 family. **2022**, 33, ○
- 125 Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies. **2022**, 23, 15384 3
- 124 Reprogramming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma. **2022**, 113, 109475 ○

- 123 Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia. 0
- 122 Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels. **2022**, 0
- 121 MicroRNAs in T Cell-Immunotherapy. **2023**, 24, 250 0
- 120 Identification of a PD-L1+Tim-1+ iNKT subset that protects against fine particulate matter-induced airway inflammation. **2022**, 7, 0
- 119 Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system. **2022**, 22, 2
- 118 Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. 12, 0
- 117 Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives. 0
- 116 Importance of lactate dehydrogenase (LDH) and monocarboxylate transporters (MCTs) in cancer cells. **2023**, 6, 0
- 115 The heterogeneity of PD-L1 protein in gastric cancer: expression and distribution characteristics. **2022**, 8, e12456 0
- 114 The effect of Wnt/ β -catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. **2022**, 30, 99-116 0
- 113 Drastic transformation of visceral adipose tissue and peripheral CD4 T cells in obesity. 13, 1
- 112 Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. 13, 0
- 111 Immune Checkpoint Therapy: A New Opportunity for Cancer Treatment. **2023**, 1-20 0
- 110 Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. **2023**, 15, 321 2
- 109 Role of B7 family members in glioma: Promising new targets for tumor immunotherapy. 12, 0
- 108 Research landscape and trends of melanoma immunotherapy: A bibliometric analysis. 12, 0
- 107 PD-L2 Blockade Exacerbates Liver Lesion in Mice Infected with *Capillaria hepatica* through Reducing Alternatively Activated Macrophages. **2023**, 8, 46 0
- 106 Pan-cancer analysis of the prognostic and immunological role of Fanconi anemia complementation group E. 13, 0

105	PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia.	2
104	Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. 2023 , 21,	0
103	Immune Checkpoint Inhibitors and Reproductive Failures. 2023 , 103799	0
102	Emerging Roles of Hedgehog Signaling in Cancer Immunity. 2023 , 24, 1321	0
101	Non-redundant upregulation of CD112R (PVRIG) and PD-1 on cytotoxic T-lymphocytes located in T-cell-nests of colorectal cancer. 2023 , 100089	0
100	Advances in PD-1 Expression Levels and Organismal Immunity in Pulmonary Infectious Diseases. 2023 , 13, 218-225	0
99	CTLA-4 inhibition facilitates follicular T-B cell interaction and the production of tumor-specific antibodies.	0
98	Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients. 1-14	0
97	Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. 2023 , 115, 109638	0
96	PD-1/PD-L1 pathway: A double-edged sword in periodontitis. 2023 , 159, 114215	0
95	Cutaneous Melanoma and Hormones: Focus on Sex Differences and the Testis. 2023 , 24, 599	0
94	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. 2022 , 8,	0
93	Metabolic reprogramming by miRNAs in the tumor microenvironment: Focused on immunometabolism. 12,	0
92	Molecular characterization of feline immune checkpoint molecules and establishment of PD-L1 immunohistochemistry for feline tumors. 2023 , 18, e0281143	1
91	Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis.	0
90	Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.	0
89	Impact of Precision Medicine in Oncology. 2023 , 29, 15-19	0
88	Androgen aggravates aortic aneurysms via suppressing PD-1 in mice.	0

- 87 Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. 14, ○
- 86 S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression. **2023**, ○
- 85 Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. 12, ○
- 84 Prospective role of PD-1/PD-L1 immune checkpoint inhibitors in GI cancer. **2023**, 154338 ○
- 83 A novel nomogram to predict lymph node metastasis in cT1 non-small-cell lung cancer based on PET/CT and peripheral blood cell parameters. **2023**, 23, ○
- 82 Targeting critical pathways in ferroptosis and enhancing antitumor therapy of Platinum drugs for colorectal cancer. **2023**, 106, 003685042211471 ○
- 81 Immunotherapies in rare cancers. **2023**, 22, ○
- 80 Characterization of peripheral blood T follicular helper (TFH) cells in patients with type 1 Gaucher disease and carriers. **2023**, 100, 102728 ○
- 79 Primary Focal Segmental Glomerulosclerosis: Why Are Pieces of This Puzzle Still Missing?. 104-110 ○
- 78 Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis. **2023**, 482, 755-766 ○
- 77 Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function. ○
- 76 Immune checkpoint molecules in prevention and development of asthma. 14, ○
- 75 TKIs in combination with immunotherapy for hepatocellular carcinoma. **2023**, 23, 279-291 1
- 74 Characterization of expression and prognostic implications of transforming growth factor beta, programmed death-ligand 1, and T regulatory cells in canine histiocytic sarcoma. **2023**, 257, 110560 ○
- 73 Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. **2023**, 117, 109881 ○
- 72 Sex-dependent PD-L1/sPD-L1 trafficking in human endothelial cells in response to inflammatory cytokines and VEGF. **2023**, 162, 114670 ○
- 71 Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. **2023**, 118, 110092 ○
- 70 A Novel Tri-Functional Liposome Re-Educates Cold Tumor and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade. 2202757 ○

- 69 Checkpoint Blockade in Hematologic Malignancies. **2022**, 1-42
- 68 Electroacupuncture Alleviates CFA-Induced Inflammatory Pain via PD-L1/PD-1-SHP-1 Pathway. **2023**, 60, 2922-2936
- 67 Characteristics of immunological events in Epstein-Barr virus infection in children with infectious mononucleosis. 11,
- 66 The Interaction of Programmed Cell Death Protein and Its Ligands with Non-Coding RNAs in Neoplasms: Emerging Anticancer Immunotherapeutics. **2023**, 11, 538
- 65 PD-1: A New Candidate Target for Analgesic Peptide Design. **2023**,
- 64 Learning from the nexus of autoimmunity and cancer. **2023**, 56, 256-271
- 63 Cancer immunotherapies: A hope for the incurable?. 3,
- 62 New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. **2023**, 24, 4044
- 61 Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma.
- 60 Review of novel functions and implications of circular RNAs in hepatocellular carcinoma. 13,
- 59 The role of LncRNAs in tumor immunotherapy. **2023**, 23,
- 58 Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy. **2023**, 22,
- 57 Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. **2023**, 13,
- 56 Advances in immune checkpoint inhibitors induced-cardiotoxicity. 14,
- 55 PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer. **2023**, 40,
- 54 Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures. **2023**, 24, 4478
- 53 The role of ubiquitin pathway-mediated regulation of immune checkpoints in cancer immunotherapy.
- 52 Identification of a copper metabolism-related gene signature for predicting prognosis and immune response in glioma.

- 51 β -adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN- γ -dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma. ○
- 50 Efficacy and Safety of Tyrosine Kinase Inhibitors Alone or Combination with Programmed Death-1 Inhibitors in Treating of Hepatitis C-Related Hepatocellular Carcinoma. Volume 10, 357-367 ○
- 49 CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy. **2023**, 13, 465 ○
- 48 Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors. 14, ○
- 47 T cell effects and mechanisms in immunotherapy of head and neck tumors. **2023**, 21, ○
- 46 Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells. **2023**, 156, 31-38 ○
- 45 Diversity of immune checkpoints in cancer immunotherapy. 14, ○
- 44 Emerging phagocytosis checkpoints in cancer immunotherapy. **2023**, 8, ○
- 43 PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis. 14, ○
- 42 The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus. 14, ○
- 41 Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma. **2023**, 100723 ○
- 40 Role of regulation of PD-1 and PD-L1 expression in sepsis. 14, ○
- 39 Current Advances in Immune Checkpoint Therapy. ○
- 38 Loss of Peroxiredoxin IV Protects Mice from Azoxymethane/Dextran Sulfate Sodium-Induced Colorectal Cancer Development. **2023**, 12, 677 ○
- 37 Novel Nanotherapeutics for Cancer Immunotherapy by PD-L1-Aptamer-Functionalized and Fexofenadine-Loaded Albumin Nanoparticles. **2023**, 28, 2556 ○
- 36 T cell co-stimulatory and co-inhibitory pathways in atopic dermatitis. 14, ○
- 35 Triptolide reduces PD-L1 through the EGFR and IFN- γ /IRF1 dual signaling pathways. **2023**, 118, 109993 ○
- 34 Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma. **2023**, 13, 3702-3708 ○

33	Structure-based small inhibitors search combined with molecular dynamics driven energies for human programmed cell death-1 (PD-1) protein. 1-15	1
32	Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment. 14,	0
31	Evaluation of Specific Cellular and Humoral Immune Response to Toxoplasma gondii in Patients with Autoimmune Rheumatic Diseases Immunomodulated Due to the Use of TNF Blockers. 2023 , 11, 930	0
30	Significance of FUT8 in Pancreatic Cancer and Others. 2023 , 105-124	0
29	Immune Molecules mRNA Expression in Porcine Alveolar Macrophages Co-Infected with Porcine Reproductive and Respiratory Syndrome Virus and Porcine Circovirus Type 2. 2023 , 15, 777	0
28	Inflammation, Infiltration, and Evasion Tumor Promotion in the Aging Breast. 2023 , 15, 1836	0
27	T-cell exhaustion in CAR-T -cell therapy and strategies to overcome it.	0
26	Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. 2023 , 15, 1909	0
25	Programmed Cell Death 1 checkpoint inhibitors as cancer therapies. 36, 8-16	0
24	A New Frontier of Neoadjuvant Immunotherapy for Hepatocellular Carcinoma. 2023 , 13, 4382-4388	0
23	Tim3 and PD-1 as a therapeutic and prognostic targets in colorectal cancer: Relationship with sidedness, clinicopathological parameters, and survival. 13,	0
22	Herbal used as Epigenetic for Cancer Treatment. 2023 , 2, 247-257	0
21	Pituitary and adrenal disorders induced by immune checkpoint inhibitors. 2023 ,	0
20	Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer. 2023 , 26, 106484	0
19	Immune Checkpoint Blockade Response Biomarkers. 2023 , 1-34	0
18	Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?. 2023 , 217-228	0
17	Nuclear PD-L1 promotes EGR1-mediated angiogenesis and accelerates tumorigenesis. 2023 , 9,	0
16	Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms. 2023 , 23,	0

- 15 An oncolytic herpes simplex virus type 1 strain expressing a single-chain variable region antibody fragment against PD-1 and a PI3K inhibitor synergize to elicit antitumor immunity in ovarian cancer. **2023**, 168, ○
- 14 ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer. **2023**, 14, ○
- 13 Virulence of Mycobacterium intracellulare clinical strains in a mouse model of lung infection: Role of neutrophilic inflammation in disease severity. **2023**, 23, ○
- 12 Regulatory factors involved in Th17/Treg cell balance of immune thrombocytopenia. **2023**, 71, 103389 ○
- 11 Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy. **2023**, 14, ○
- 10 Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. **2023**, 23, ○
- 9 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 8 Novel strategies for cancer immunotherapy: counter-immunoediting therapy. **2023**, 16, ○
- 7 Complete Remission of a Patient With HER-2 amplification Gastric Cancer Treated With Sintilimab Combined With Trastuzumab. ○
- 6 Evaluation of the immune checkpoint factors in idiopathic membranous nephropathy. **2023**, 69, 101914 ○
- 5 Nano-immunotherapy for lung cancer. **2023**, 2, e9130018 ○
- 4 Immunotherapy with or without targeted therapy for metastatic upper tract urothelial carcinoma: case report and literature review. **2023**, 9, e15813 ○
- 3 Gene expression analysis of Canine Demodicosis; A milieu promoting immune tolerance. **2023**, 319, 109954 ○
- 2 Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial-Mesenchymal Transition. ○
- 1 Epigenetic reprogramming of Runx3 reinforces CD8 + T-cell function and improves the clinical response to immunotherapy. **2023**, 22, ○